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 Major depressive disorder (MDD) is the second most common mental health 
condition and a leading cause of disability in the world.  It is theorized that MDD 
develops from a combination of biological, psychological, and social stressors.  The 
condition is typically treated using pharmaceuticals and psychotherapy.  However, not all 
individuals with MDD have access to or choose to use these treatments, or may prefer to 
incorporate therapeutic lifestyle changes such as exercise, sleep, and healthy eating.  
Even with treatment, MDD can alter brain structure and function, leading to the 
development of comorbid mental health and chronic metabolic conditions like obesity, 
cardiovascular disease, or diabetes.  Physiological mechanisms that can be significantly 
affected by MDD episodes include brain glucose metabolism, brain-derived neurotrophic 
factor (BDNF) production and activity, and antioxidant function.  This paper reviews 
existing literature to examine these components of the pathophysiology of MDD and 
outline how treatments could functionally improve the condition.  Most research has 
examined the relationship between nutrition and MDD utilizing traditional interventions, 
like low-fat diets, but more recent studies have explored alternative nutrition therapies.  
Animal-models have shown potential for the use of the ketogenic diet as nutrition therapy 
for MDD by demonstrating improved metabolism of alternative nutrients, increased 
BDNF activity, and improved antioxidant capacity in the brain.  However, to date, there 
are no studies that examine the effects of a ketogenic diet on a human population with 
MDD.  Future research is warranted to determine whether a ketogenic diet is a safe and 





Chapter I. Review of Literature 
Introduction 
MDD, also known as clinical or major depression, has a significant impact on the 
personal, social, familial, and occupational function of millions of individuals in the US 
and the rest of the world. According to the World Health Organization (WHO), MDD 
was the fourth highest cause of disability in the world in 2013 and is on course to be the 
second highest by the end of 2020.1  While the lifetime incidence of MDD has been 
estimated to be between 15 to 20%, there was a 10-year prevalence rise from 6.6% in 
2005 to 7.3% in 2015.1, 2  The incidence of MDD among the general population is 
characterized by a variety of demographic, socioeconomic, and lifestyle factors.  
Reported rates of MDD tend to be significantly higher among females,2, 3 individuals less 
than 45 years old,2, 3 non-Hispanic white and Hispanic populations,2, 3 individuals with 
annual incomes below $20,000,2 and individuals with at least some college education.2  
Research has also revealed that MDD is two to three times more common in individuals 
who already have multimorbidities compared to those with one or no chronic physical 
conditions.4  This data indicates a potential risk for a cyclical or synergistic pattern of 
MDD and chronic disease, due to the inflammatory effect that MDD has on human 
physiology. 
It has been estimated that about 56% of individuals who have depression and at 
least one other chronic physical condition use antidepressants for treatment, while about 
21% use psychotherapy, and about 22% report no treatment.5  With research indicating 
that diet, sleep, and exercise all have a significant impact on the development, 




pharmacological interventions that address these factors, especially among those 
individuals not currently following any treatments for MDD.6  Additionally, the 
correlation between poor mental and physical health and the prevalence of individuals 
with multimorbidities warrants further research into intervention methods that can 
improve multiple health conditions.  To date, most research has utilized dietary 
interventions that emphasize a higher intake of fruits, vegetables, and whole grains, 
following a low-fat diet or exchanging high saturated fat foods for those high in 
unsaturated fats or limiting the consumption of foods that are highly processed or contain 
high amounts of added sugars.7  However, with the continued rise in the prevalence of 
depression, it would be beneficial to continue research into the effects of nontraditional 
dietary interventions that do not necessarily strictly follow to these typical eating 
patterns.  Therefore, this critical review will describe the pathophysiology of major 
depressive disorder, including brain nutrient metabolism and oxidative stress, and the 
relationship between major depression and obesity.  Additionally, it will review current 
research regarding the high-fat, low-carbohydrate ketogenic diet and its mechanistic 
action on neurophysiological systems that are dysregulated in major depression to outline 
the therapeutic potential of this type of dietary intervention in the treatment of the 
condition.  
Major Depressive Disorder 
To better comprehend the prevalence and effects of MDD, it is necessary to 
understand its status as a mental health condition and how it is categorized and diagnosed 
by mental health professionals.  MDD is classified as a neuropsychiatric mood disorder 




activities.  According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition (DSM-V), the criteria for a diagnosis of MDD require that8: 
I. Five (or more) of the following symptoms have been present during the same 2-week 
period and represent a change from previous functioning; at least one of the symptoms is 
either (1) depressed mood or (2) loss of interest or pleasure. 
A. Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g., feels sad, empty, hopeless) or observation made by others 
(e.g., appears tearful). 
B. Markedly diminished interest or pleasure in all, or almost all, activities most of 
the day, nearly every day (as indicated by either subjective account or 
observation). 
C. Significant weight loss when not dieting or weight gain (e.g., a change of more 
than 5% of body weight in a month), or decrease or increase in appetite nearly 
every day. 
D. Insomnia or hypersomnia nearly every day. 
E. Psychomotor agitation or retardation nearly every day (observable by others, not 
merely subjective feelings of restlessness or being slowed down). 
F. Fatigue or loss of energy nearly every day. 
G. Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being sick). 
H. Diminished ability to think or concentrate, or indecisiveness, nearly every day 
(either by subjective account or as observed by others). 
I. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide. 
II. The symptoms cause clinically significant distress or impairment in social, occupational, 




III. The episode is not attributable to the physiological effects of a substance or another 
medical condition. 
IV. The occurrence of the major depressive episode is not better explained by schizoaffective 
disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other 
specified and unspecified schizophrenia spectrum and other psychotic disorders. 
V. There has never been a manic episode or a hypomanic episode.  
A diagnosis of MDD can include either isolated or recurrent episodes, which are typically 
classified as mild, moderate, or severe.  For individuals with MDD, the length and 
severity of an episode can have a lasting impact on brain structure and function, while 
recurrent or chronic MDD is likely to lead to the development of other chronic health 
conditions. 
Neuropathology. 
 MDD is considered to be caused by a combination of various biological, 
psychological, and social stressors.  These factors are likely to alter several components 
of brain function, in addition to creating an inflammatory state within the body that can 
affect multiple physiological organ systems.  Some of these functions with which MDD 
interferes in the human body include brain glucose metabolism, regulation of brain-
derived neurotrophic factor (BDNF), and antioxidant activity. 
Glucose metabolism. Although glucose is typically the main source of energy for 
the brain, there are significant alterations in the mechanisms of glucose metabolism in 
populations affected by major depression.  Several studies, examining individuals with 
MDD and concurrent anhedonia, have demonstrated regional glucose hypometabolism 
and metabolic asymmetry in the left prefrontal cortex, cerebellum, left anterior cingulate, 




middle temporal gyrus, and right superior temporal gyrus.9-11 These alterations have also 
been associated with the relative severity and course of the depressive episode, such that 
individuals with severe depression are likely to have lower global cerebral glucose 
metabolic rates.12  It has been shown that successful pharmacological treatment, with 
specific antidepressants, can increase glucose utilization in the left prefrontal cortex; 
however, whole frontal glucose metabolism was still significantly lower in both untreated 
and treated MDD individuals.10   Holthoff et al. even reported decreases in regional 
glucose metabolism in remitted MDD patients treated with selective serotonin reuptake 
inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).9  These 
results demonstrate that specific antidepressant treatments may not induce long-term 
changes in or may have absolute detrimental effects on cerebral glucose metabolism.  A 
possible causal link between MDD and decreased cerebral glucose metabolism was found 
by Kahl et al., showing that elevated DNA methylation of GLUT1 in unremitted MDD 
patients lowered GLUT1 expression in brain cells, but could be reversed through MDD 
remission.13  Although the main alterations to cerebral metabolism are related to glucose 
metabolic dysfunction, Mocking et al. reported another change in cerebral metabolism, 
which included elevated fatty acid unsaturation and peroxidation that was negatively 
associated with higher cortisol levels in individuals with MDD.14  These findings indicate 
that glucose uptake from blood vessels into the brain may be compromised in untreated 
and treated MDD and that another source of energy could potentially improve cerebral 
metabolic rates for these individuals. 
BDNF.  Although brain metabolic dysfunction is an important factor in the 




changes to the activity of BDNF.  BDNF is the most abundant neurotrophin in the 
nervous system and is involved in the development and regulation of neuronal systems, 
neurotransmitter activity, and neuroplasticity.15, 16  Individuals with MDD have been 
shown to have significantly lower concentrations of serum BDNF in comparison to 
healthy controls.15, 17-22  Lower serum BDNF levels have also been reported during 
recurrent depressive episodes as compared to first episodes,17 in individuals with long-
term MDD (≥1 year) as compared to short-term MDD (<1 year),23 and in individuals with 
MDD as compared to individuals with dysthymia.20  However, Sözeri-Varma et al. did 
find a contrasting result by demonstrating that there was no significant difference in 
serum BDNF levels between individuals in their first and recurrent MDD episodes.18  In 
regard to the correlation between MDD treatment and BDNF activity, it has been 
demonstrated that antidepressants can increase serum BDNF levels in individuals with 
MDD.15, 19, 22  While these findings do not indicate that antidepressants only treat MDD 
by improving BDNF levels, it has been suggested that low BDNF levels play an 
important role in the pathophysiology of MDD and other affective disorders.15, 19, 22 
Although most data appears to support this hypothesis, there is no evidence for 
directionality in this relationship, and conflicting data has been shown between serum 
BDNF levels and the severity of MDD and the presence of psychotic features.17, 18, 23  The 
correlation between improvements to reduced BDNF levels and the severity of MDD 
symptoms warrants additional research, especially regarding treatments and interventions 
that can improve both of these conditions. 
Oxidative Stress.  Other prevalent alterations to brain function in MDD can occur 




structure and metabolism, and neuronal interaction.  Markers of oxidative stress and 
reduced antioxidant function have been repeatedly noted in individuals with MDD 
compared to healthy controls.24-28  The major brain antioxidant glutathione, its 
complementary enzyme glutathione peroxidase (GPx), and the detoxifying brain isozyme 
glutathione S-transferase Mu 1 (GST Mu 1) were shown to be significantly lowered in 
post-mortem brain tissues of individuals with MDD, bipolar disorder, and 
schizophrenia24, 29 and the serum of living individuals with MDD.25, 28  There has been 
one report of no difference in GPx activity between individuals with MDD and healthy 
controls.26  While the previously mentioned enzymes are typically reduced during MDD, 
there have also been reports of increased activity of the antioxidant enzymes glutathione 
reductase,25,29 superoxide dismutase (SOD),25, 29, 30 and catalase.26, 30  However in contrast 
to this, Rybka et al. did find decreased SOD activity in individuals with MDD compared 
to healthy controls.28  Additionally, some of these antioxidant activities have not been 
shown to improve or have even been slightly suppressed with the pharmacological 
treatment of MDD.26, 29, 30  These findings illustrate that oxidative stress in psychiatric 
conditions, including MDD, may be exacerbated by antioxidant dysregulation and 
dysfunction.  Markers of oxidative stress, such as malondialdehyde, 8-OH 2-
deoxyguanosine, interleukin-6, tumor necrosis factor-α (TNF-α), F2-isoprostanes, 
neopterin have also been found in elevated levels in individuals with MDD, and some 
have been associated with decreased effectiveness of antidepressant treatments.27-29  
Interleukin-6 levels, however, were shown to be decreased by SSRI treatment.27 The 




stress in MDD suggests that other therapeutic methods should be examined for the 
limitation of prooxidant and enhancement of antioxidant systems. 
Obesity. 
Due to its similar relationship with increased oxidative stress and systemic 
inflammation, it is important to discuss obesity and how it correlates with MDD.  There 
have been numerous large-scale, cross-sectional epidemiological and observational 
studies that have examined this relationship, and have demonstrated a positive correlation 
between obesity and MDD.31-35  Some studies have reported odds ratios between 1.1 and 
2.09 for the risk of developing MDD when the condition is preceded by obesity.32, 36 
Several studies have reported that this association occurs mainly between MDD and 
severe or class III obesity (body mass index ≥ 40 kg/m2).31, 37, 38 Despite this significant 
correlation, no causal direction of the MDD-obesity relationship has been officially 
established.  However, in their research based on the Alameda County Study, Roberts et 
al. did report that obesity at baseline was associated with an increased risk of MDD five 
years later, while the presence of MDD at baseline did not increase the risk of future 
obesity when controlling for baseline obesity.32  In this study, the sample was collected 
from the 1994 and 1999 waves of the Alameda County cohort, including 2,123 
individuals who were 50 years or older.  This finding suggests a possible causal 
relationship for the obesity-to-MDD direction, but not vice versa; however, to the 
knowledge of the researchers, this result has not been obtained in any other research.  It 
has been shown that the presence of overweight or obesity in individuals with MDD is 
associated with slower clinical and neuroendocrine responses to antidepressant 




reduction in the severity of MDD, with individuals achieving greater weight loss also 
experiencing the largest reduction in MDD severity.38  The importance of treating MDD 
is further emphasized by the correlation between the presence of a current or lifetime 
MDD diagnosis, in addition to obesity, and an increased risk for the development of other 
psychiatric disorders, smoking, physical inactivity, alcohol and substance abuse, 
disordered eating, and other unhealthy behaviors.31, 33, 36  Although these findings did not 
determine a specific causal direction in the MDD-obesity relationship, they do suggest 
the dire need for a multifactorial and comprehensive approach to the treatment of MDD 
and obesity, beyond pharmaceuticals, especially when the conditions are concurrently 
present. 
Ketogenic Diet 
Traditional treatments for MDD may not always be effective in managing 
physiological consequences of the condition, especially when individuals are 
experiencing reduced glucose metabolism in the brain, increased levels of oxidative 
stress, or have multiple comorbidities. A possible alternative or complementary treatment 
for MDD would be a dietary intervention of the ketogenic diet, which is a high-fat, very 
low-carbohydrate, adequate-protein eating plan.  Typically, it includes an initial reduction 
of net carbohydrate intake to less than 20 to 50 grams per day with a macronutrient 
distribution of approximately 0-10% carbohydrate, 60-80% fat, and 10-30% protein as a 
percent of total energy intake.40  This severe restriction of carbohydrates lowers glucose 
availability, thereby decreasing insulin and increasing glucagon concentrations.  This 
creates a metabolic shift in the body away from fat storage to lipolysis and β-oxidation by 




endogenous protein and fat sources can provide energy, and glucose concentrations can 
be relatively maintained without carbohydrate intake.40  The ketogenic diet’s alternative 
nutrient utilization is one of its most important characteristics and may be highly 
beneficial for the MDD population as they typically have significantly reduced glucose 
metabolism in the brain.  The subsequent sections describe the mechanisms of action 
related to the ketogenic diet in brain nutrient metabolism, the production of BDNF, 
regulation of oxidative stress, and weight management that could improve the 
physiological consequences of MDD. 
Neurophysiology. 
Ketone Metabolism.  As the ketogenic diet restricts carbohydrate intake to a level 
at which the body is not able to maintain carbohydrate utilization throughout all tissues, it 
is necessary that the body more effectively use lipids and their metabolites for energy.  
When energy is mainly provided by fatty acid oxidation in cell mitochondria, large 
amounts of acetyl-CoA are produced, which are then utilized, primarily in the liver, to 
synthesize the ketone bodies β-hydroxybutyrate (β-HB), acetoacetate and acetone.42 
Ketosis occurs when the metabolic efficiency of the Krebs, or tricarboxylic acid (TCA) 
cycle, is reduced and additional acetyl-CoA is converted into ketones.42  Because the 
liver does not have succinyl CoA:3- ketoacid CoA transferase, a mitochondrial enzyme 
that converts acetoacetate to acetoacetyl CoA, ketone bodies are forced into the 
circulatory system.43  In ketosis, the levels of the ketone bodies β-HB, acetoacetate, and 
acetone are increased in the peripheral blood and urine.  These ketones are delivered to 
and serve as a fuel source for numerous extrahepatic tissues, including the brain.42, 44 This 




fulfill its normal fuel-based functions.  Higher levels of ketosis will proportionally spare 
glucose from metabolism in the brain and other tissues.44  This mechanism has great 
significance in conditions in which glucose availability can be severely limited, as fatty 
acids are not able to cross the blood-brain barrier to provide energy.  This sparing effect 
of ketones for glucose in cerebral metabolism has been shown in rat models and has 
demonstrated a coordinated upregulation of energy metabolic genes and an increase in 
metabolic gene transcripts.44, 45  To the knowledge of the researchers, no current research 
has demonstrated these findings in any human population.  Despite this lack of research, 
the ketogenic diet provides an alternative source of energy for the brain, which could 
benefit individuals with MDD who experience significantly reduced brain glucose 
metabolism. 
BDNF Activity and the Ketogenic Diet.  Another aspect of brain function 
affected by ketone bodies is the concentration and activity of BDNF.  Although no 
studies have demonstrated in vivo action of ketones on the expression of BDNF in 
humans, in vivo and vitro animal models have shown ketone-mediated alterations in 
BDNF gene expression and protein levels.46-49  At least two models have examined the 
direct effects of a ketogenic diet on BDNF activity.  Genzer et al. showed an increase in 
the BDNF:proBDNF ratio, whole brain and liver BDNF expression, and BDNF mRNA in 
a population of C57BL/6 male mice fed an ad libitum ketogenic diet.46  This finding 
suggests a ketone-induced upregulation of BDNF production, especially in the brain.  
However, Vizuete et al. demonstrated that BDNF content was decreased in the corpus 
striatum, but not the hippocampus, in male Wistar rats fed a ketogenic diet.48  These 




total BDNF gene expression and content but reducing regional BDNF synthesis.  Another 
in vivo study examined the indirect effects of a ketogenic diet on BDNF activity by using 
2-deoxy-D-glucose to induce ketogenesis and ketosis in 3xTgAD mice. In this study, Yao 
et al. found that 2-deoxy-D-glucose-induced ketosis did not adversely affect 
mitochondrial function in neurons or mixed glia and stimulated the upregulation of the 
BDNF and another neurotrophic factor, nerve growth factor (NGF).49  In an in vitro study 
of exercised male C57BL/6 mice, β-HB was found to increase with exercise and 
coincided with an increase in BDNF expression and protein levels in cortical neurons.47  
This finding is consistent with the results of the previously discussed in vivo studies, as it 
suggests that β-HB is involved in the in vivo regulation of BDNF.  Although these studies 
have only examined animal models, they indicate that there could be benefits of using a 
ketogenic diet in conditions like MDD, in which BDNF expression or protein levels are 
lowered. 
Oxidative Stress and the Ketogenic Diet.  In addition to the previously mentioned 
metabolic and neurological alterations, the ketogenic diet has been shown to have 
significant impact on both systemic and brain oxidant-antioxidant systems.  The theorized 
neuroprotective effect of the ketogenic diet is associated with acetoacetate and β-HB and 
has only been demonstrated in animal models.  These studies have shown that a 
ketogenic diet, via acetoacetate and β-HB action, can protect hippocampal and 
dopaminergic neurons from glutamate-induced or 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) excitotoxicity and can increase glutathione synthesis, Nrf2 
protein levels, NAD(P)H dehydrogenase quinone 1 (NQO1) activity.50-53  The 




protective mechanism against oxidative damage and improvements in mitochondrial 
redox status.  Several animal studies have shown the indirect effects of the ketogenic diet 
in mediating oxidative stress by decreasing reactive oxygen species (ROS) and free 
radicals and enhancing mitochondrial antioxidant capacity.53-55  It is suggested that the 
reduction in ROS production is achieved by improving mitochondrial uncoupling protein 
activity, which reduces the membrane potential upon which the ROS production is 
dependent.55  The ketogenic diet has also been shown to improve hippocampal 
mitochondrial antioxidant capacity, specifically by increasing NQO1, SOD1, and GPx 
expression and decreasing catalase activity in animal models.56, 57  These animal-based 
studies demonstrate that the ketogenic diet has the potential for reliable antioxidant, anti-
inflammatory, and neuroprotective capabilities in conditions, like MDD and obesity, that 
are adversely affected by systemic and neural oxidative stress and inflammation.  
However, more research is needed to determine if the ketogenic diet can reliably improve 
antioxidant capacity and reduce oxidative damage in humans. 
Mood Changes with the Ketogenic Diet. 
Several animal studies have demonstrated possible antidepressant or mood-
improving properties of the ketogenic diet; however, the exact mechanisms have not been 
established. Two of these studies appeared to show that a ketogenic diet, mainly through 
the action of β-HB, reduced “behavioral despair”  in stressor-exposed male Wistar rats 
and depressive-like behaviors in stressor-exposed male C57BL/6J mice.58, 59  One severe 
limitation of the study by Huang et al. is that they did not assess whether ketosis was 
necessary to induce the behavioral change.59  However, similar results were replicated in 




received daily β-HB injections (300 mg/kg), another group received a ketogenic diet, and 
both were exposed to severe stressors and compared to separate controls.60  The results of 
this study demonstrated that exogenous β-HB improved depressive behaviors, and 
mitigated the reduction of Histone3-lysine9-β-hydroxybutyrylation (H3k9βhb) and 
BDNF.  Another animal study examined the offspring of female CD-1 mice that had 
followed a ketogenic diet during gestation and found that prenatal exposure to a 
ketogenic diet altered the offspring’s’ neuroanatomy and improved their resistance to the 
development of anxiety and depression in adulthood.61  The primary changes to 
neuroanatomy in these offspring compared to controls were cerebellar volumetric 
enlargement by 4.8%, a hypothalamic reduction by 1.39%, and a corpus callosum 
reduction by 4.77%, relative to total brain volume.  In human-based studies, ketogenic 
diets have been shown to have varying effects on mood and behavior in comparison to 
low-fat diets, such as decreasing markers of anxiety, but not affecting those of 
depression62, demonstrating higher levels of fatigue, but lower levels of social 
antagonism63, and impairing memory performance, but supporting sustained attention.64  
A study conducted in a human sample by Halyburton et al. compared the effects of a low-
carbohydrate ketogenic diet to a high-carbohydrate diet on mood and cognitive 
performance.65  These researchers showed that both diets were effective in improving 
mood, with no difference in effectiveness, but that the low-carbohydrate ketogenic diet 
improved cognitive processing speed more than the other dietary intervention.  However, 
the generalizability of this study is limited to “healthy, overweight and obese, young to 
middle-aged adults with normal mood state and no cognitive impairment”, and not 




elucidate the influence of the ketogenic diet on improving characteristics of mood that are 
specifically affected in individuals with MDD. 
 Obesity and the Ketogenic Diet. 
 While the primary purpose of this narrative review is to outline the therapeutic 
potential of a ketogenic diet in treating MDD, it also seeks to confirm previously 
demonstrated effects of the ketogenic diet on body composition, especially in overweight 
and obese populations.  Because of the elevated risk for these populations to develop 
MDD, other psychiatric disorders, and chronic metabolic diseases, it would be beneficial 
to identify treatments that improve both mental and metabolic health conditions.  Within 
the literary body of evidence, there is varying data regarding the effectiveness of the low-
carbohydrate ketogenic diets in comparison to other traditional weight-loss dietary 
interventions.  Numerous studies of the ketogenic diet have demonstrated significantly 
greater improvements in weight loss and reductions in abdominal and visceral obesity in 
comparison to low-fat 66-74 and Mediterranean75 diets.  A follow-up study by Dyson et al. 
determined that the weight loss effect of the ketogenic diet was higher than that of a low-
fat diet immediately following the intervention and at 6 months, but that this effect was 
no longer significantly different at two years after the intervention.76  Several studies 
have shown improvements in body weight and obesity with the ketogenic diet but 
without any comparison to a control group.77-80  The primary theory regarding the greater 
effectiveness of the ketogenic diet for weight loss is that they work indirectly by 
restricting total energy intake due to sustained satiety and energy expenditure, increased 
fatty acid oxidation, and a sparing effect on fat-free mass.81  In contrast to this data 




while the ketogenic diet does induce weight loss, it is no more effective than low-fat, the 
Mediterranean, or non-ketogenic low carbohydrate diets for the treatment of obesity.72, 81-
93  The primary theory for the ketogenic diet having no greater effectiveness than other 
traditional weight-loss diets is that all weight-loss diets have relatively similar total 
energy intakes and that there is no metabolic advantage to one or more particular 
macronutrients.  The correlation between MDD and obesity supports further research into 
and the utilization of therapies like the ketogenic diet that can improve both conditions 
through multiple physiological mechanisms.  
 Biomarker Alterations with the Ketogenic Diet. 
 The association between biomarkers such as serum lipids and glucose and the 
oxidative stress and inflammation induced through MDD and chronic metabolic diseases 
has been well established.  However, the evidence for the impact of a ketogenic dietary 
intervention on these biomarkers is highly ambiguous.  Based on numerous studies 
examining the use of the ketogenic diet for weight-loss intervention and improvement of 
metabolic risk factors, it has been shown that the ketogenic diet has more significant 
effects on lipid profiles, glycemic control, and insulin resistance, and proinflammatory 
markers compared to traditional weight-loss diets.  Some studies have shown a serum 
lipid response to a ketogenic diet that includes an increase in total cholesterol,75, 81 low-
density lipoprotein (LDL),66, 75, 79, 83, 90-93 high-density lipoprotein (HDL),66, 69, 74, 75, 77, 79, 
80, 83, 90, 92-94 and a decrease in triglycerides (TG).66, 74, 75, 77, 82-85, 93-97  Other studies have 
shown different effects on serum lipids leading to unchanged or decreased HDL,73, 77, 79, 
89, 95 TGs,73, 79, 80 total cholesterol,69, 73, 74, 77, 80, 94, 98 and LDL.69, 73, 74, 80, 94-97  The 




94 or glycated hemoglobin (HbA1c),82 decreased insulin,69, 79, 90, 92 and decreased insulin 
resistance.85, 86, 98  The inflammatory markers that may be decreased in individuals 
following a ketogenic diet include TNF-α,97, 99, 100 interleukin-6,97, 100 interleukin-8,97 
monocyte chemoattractant protein 1 (MCP1),97 E-selectin,97 intercellular adhesion 
molecule 1 (I-CAM),97, 100 and C-reactive protein (CRP).90, 97, 100  However, Cardillo et al. 
found no change in serum CRP following a ketogenic dietary intervention.99  These 
biomarkers are an important indicator of health as they are correlated with chronic stress 
and inflammation that can lead to the development of comorbid metabolic and psychiatric 
conditions.  Based on the research regarding the influence of the ketogenic diet on 
metabolic biomarkers, the ketogenic diet may be beneficial for individuals with issues of 
glycemic control; however, there is no consensus regarding improvements to lipid 
markers as an effect of the ketogenic diet.  Further research could provide valuable data 
to this area of literature, specifically by examining the effects of the ketogenic diet on 
these biomarkers in populations with MDD and other mood disorders. 
Study Justification 
 The purpose of this review is to demonstrate the potential of the ketogenic diet to 
be utilized as a medical nutrition therapy for MDD.  To the knowledge of the researchers, 
no past reviews have outlined how the ketogenic diet could functionally affect these 
physiological mechanisms of MDD.  This narrative review briefly illustrates the 
prevalence of MDD, describes the physiological changes that occur from the condition, 
and identifies the increased risk for the development of obesity and other metabolic 
diseases. Animal models have shown the capability for the use of this diet as nutrition 




metabolism, increased BDNF activity, and improved antioxidant capacity in the brain.  
These physiological effects of the ketogenic diet support its utilization in research for 
populations that have MDD and comorbid psychological and metabolic conditions.  The 
current state of literature presents an opportunity for psychology and nutrition researchers 
to progress from animal models to examine whether these effects are observable in a 
human population while further assessing mood and the psychological characteristics of 
MDD.  Furthermore, the advancement of knowledge in this area may help mental health 
care providers and nutrition professionals to better address the individual needs of their 





Chapter II. Methodology 
 This research project was originally designed as a randomized controlled trial to 
examine whether a 12-week high-fat, low-carbohydrate ad libitum ketogenic diet alone 
reduces depression severity and improves body composition more effectively than an ad 
libitum Dietary Approaches to Stop Hypertension (DASH) diet in a population of 
military veterans.  However, due to the COVID-19/coronavirus pandemic at the 
beginning of 2020, this study was terminated and transitioned to a literature review to 
eliminate any risk of infection for participants and researchers.  The provided approved 
methodology describes the processes through which the original dietary interventions 
were supposed to be conducted. 
Participants 
 Initially, a total of 50 male and female veterans were expected to be recruited by 
public advertisement to participate in a 12-week dietary intervention.  After Institutional 
Review Board (IRB) approval, participants were recruited from the Martinsburg Veterans 
Affairs Medical Center and its community-based outpatient clinics in the Shenandoah 
Valley region of Virginia through recruitment flyers and a bulk email distributed to 
James Madison University faculty, staff, and students (Appendix A).  The primary 
inclusion criterion for participation was status as a veteran of any branch of the United 
States Armed Forces.  Before recruitment was discontinued due to the COVID-19 
pandemic, a total of 15 eligible individuals contacted the researchers; however, after 
being provided with an outline of the study participation requirements only 7 males and 1 
female (n=8) elected to proceed with the informed consent.  Participants were assessed 




Inventory-II (BDI-II) (Appendix B).  Before the study commencement, all participants 
completed a health screening questionnaire (Appendix B), which was used to determine 
whether they met the inclusion and exclusion criteria.  One additional inclusion criterion 
was for participants to be between the ages of 18-65 years.  Participants were also eligible 
to be included if they had a diagnosed anxiety disorder or post-traumatic stress disorder, 
so long as major depression was a primary diagnosis as determined by a physician or 
mental health professional.  The use of antidepressants or anxiolytics was allowed if the 
participant had been consistently using these medications for ≥ 8 weeks.  Any change in 
antidepressant or anxiolytic medication type during the intervention would disqualify 
participants from continued participation.  Participants were also able to use antidiabetic 
(including insulin), antihyperlipidemic, or antihypertensive medications if they have been 
consistently taken for ≥ 2 weeks, ≥ 8 weeks, and ≥ 2 weeks, respectively.  Exclusion 
criteria included: weight instability (± 4.5 kg in the past 6 months); use of a low or no 
carbohydrate diet in the past 3 months; diagnosis of any psychological disorders other 
than major depressive disorder, an anxiety disorder, or post-traumatic stress disorder; use 
of mood stabilizers or antipsychotics. 
 The protocol and the potential risks and benefits of the study were fully explained 
to all participants before they provided written informed consent.  All experimental 
procedures were approved by the IRB of James Madison University. 
Study Design 
 In a parallel study design, eligible participants were randomly assigned to follow 
an ad libitum low-carbohydrate ketogenic dietary intervention (LCKD) or ad libitum 




prescribed dietary intervention, participants were asked to maintain their usual lifestyle 
and activity throughout the study.  At baseline (week 0), week 6, and week 12, 
participants would attend testing after an overnight fast.  Details of the data collection 
methods for this testing are discussed in the following sections. 
Dietary Intervention 
 Although both dietary interventions were prescribed as ad libitum, participants 
were provided general information about adequate nutrition practices. The estimated 
macronutrient distribution for each dietary intervention is as follows: the LCKD with 25-
30% of total energy as protein, 65-70% as fat, and 5-10 % as carbohydrate; the DASH 
with 15-20% of total energy as protein, 30-35% as fat, and 50-55% as carbohydrate.  
Participants in the LCKD group were to be restricted to < 50g of total carbohydrates per 
day throughout the 12-week intervention to maintain their state of ketosis.  To facilitate 
dietary compliance, participants in both groups received individualized handouts 
containing recipes, online resources, a list of foods that could assist them in meeting their 
nutritional needs and foods that should be avoided, and tips for maintaining their assigned 
dietary intervention (Appendix C).  A consecutive four-day food record (3 weekdays, 1 
weekend day) was to be collected and analyzed at weeks 0, 4, 8, and 12 either during an 
in-person meeting or phone call.  This analysis was to be conducted using the Nutrition 
Data System for Research (NDSR) software (University of Minnesota Nutrition 
Coordinating Center, Minneapolis, MN).  Additionally, participants assigned to the 
LCKD were supposed to complete a weekly dietary compliance checklist to ensure 
adherence to the assigned diet.  If participants consumed any of the listed carbohydrate-




this information to the researchers at the end of each week.  These checklists were 
intended to be used by researchers to assess participants’ adherence to the assigned 
dietary guidelines and to prompt a personalized dietary education session to guide the 
participant back into dietary compliance if needed. 
Clinical Measures 
 Body height was measured to the nearest 0.1 cm and body weight was measured 
to the nearest 0.05 kg using a MedVue® medical weight analyzer with a stadiometer 
(Detecto; Missouri).  Both measures were taken while participants were barefoot and in 
light clothing.  Body composition, specifically fat mass, fat-free mass, and body fat 
percentage were assessed using a dual-energy X-ray absorptiometry (DXA) scan 
(Illuminatus DXA, Norland at Swissray; Fort Atkinson, WI), while participants were 
supine in light clothing with no metal or footwear.  Blood pressure was assessed by 
researchers using a sphygmomanometer, in a supine position, immediately following the 
DXA scan.  Blood pressure measurement procedures followed the American College of 
Sports Medicine’s Guidelines for Exercise Testing and Prescription.101 These clinical 
measures were to be collected at weeks 0, 6, and 12. 
Questionnaires 
 The severity of major depressive disorder was assessed using the Beck 
Depression Inventory-II (BDI-II), which is a 21-question self-report inventory and a 
reliable and well-validated measure (Appendix B).102  A high score on the BDI-II 
indicates a higher severity of the depressive state.  The presence and severity of anxiety 
were assessed using the Beck Anxiety Inventory (BAI), which is a 21-question self-report 




International Physical Activity Questionnaire-Long Form (IPAQ-L) is a self-
administrable, 27-question measure, which produces estimates of physical activity in five 
domains: work, transportation, household, leisure, and sedentary time (Appendix B).  The 
IPAQ-L has demonstrated good reliability and validity in research.104 These 
questionnaires were to be completed by the participants during the laboratory testing 
sessions at weeks 0, 6, 12. 
Biochemical Analysis 
 Fasted capillary blood samples were collected through fingersticks using blood 
lancets.  Fasting blood glucose, a full serum lipid profile [including high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides (TG), total cholesterol], 
and serum ketone measures were taken and analyzed using a CardioChek PLUS Blood 
Analyzer (PTS Diagnostics; Indiana) and the appropriate testing strips.  These measures 
were to be completed at weeks 0, 6, and 12. Additionally, urinary ketones were to be self-
assessed daily by participants assigned to the LCKD, using URiSCAN® Ketones Urine 
Test Strips (YD Diagnostic Corp; South Korea).  These results were to be recorded in a 
written log and provided weekly to researchers to assess the presence of ketosis and 
ensure LCKD dietary compliance.  Each week, LCKD participants were expected to meet 
compliance with ketosis (positive urinary ketone test) for ≥ 6 days, or they would be 
removed from the study. 
Statistical Analysis 
 The sample size was determined using the National Statistical Service Sample 
Size Calculator (Australian Bureau of Statistics).  The confidence level was set at 95%.   




these individuals is expected to yield a 0.069 proportion of individuals with MDD.105  It 
was determined that the sample size for this study requires a minimum of 25 and a 
maximum of 99 participants to achieve confidence intervals of 0.10 and 0.05 
respectively. 
Before hypothesis testing, data was to be examined for normality using the 
Shapiro-Wilk test. Statistical analyses were to be performed with SPSS software (version 
26.0; IBM; New York). Between-group differences in baseline characteristics were to be 
assessed using independent t-tests for continuous variables and Pearson chi-square test 
for categorical variables.  The effects of the dietary intervention on psychological and 
biochemical variables were to be determined using repeated-measures analysis of 
variance (ANOVA) with time as the within-subject factor and diet (LCKD vs. DASH) 





Chapter III. Manuscript 
 
Therapeutic Potential of a Ketogenic Diet in the Treatment of 




Major depressive disorder (MDD) is the second most common mental health condition 
and a leading cause of disability in the world.  It is theorized that MDD develops from a 
combination of biological, psychological, and social stressors.  The condition is typically 
treated using pharmaceuticals and psychotherapy.  However, not all individuals with 
MDD have access to or choose to use these treatments, or may prefer to incorporate 
therapeutic lifestyle changes such as exercise, sleep, and healthy eating.  Even with 
treatment, MDD can alter brain structure and function, leading to the development of 
comorbid mental health and chronic metabolic conditions like obesity, cardiovascular 
disease, or diabetes.  Physiological mechanisms that can be significantly affected by 
MDD episodes include brain glucose metabolism, brain-derived neurotrophic factor 
(BDNF) production and activity, and antioxidant function.  This paper reviews existing 
literature to examine these components of the pathophysiology of MDD and outline how 
treatments could functionally improve the condition.  Most research has examined the 
relationship between nutrition and MDD utilizing traditional interventions, like low-fat 
diets, but more recent studies have explored alternative nutrition therapies.  Animal-
models have shown potential for the use of the ketogenic diet as nutrition therapy for 
MDD by demonstrating improved metabolism of alternative nutrients, increased BDNF 
activity, and improved antioxidant capacity in the brain.  However, to date, there are no 




Future research is warranted to determine whether a ketogenic diet is a safe and reliable 
medical nutrition therapy for MDD. 
INTRODUCTION 
 Major depressive disorder (MDD), also known as clinical or major depression, 
has a significant impact on the personal, social, familial, and occupational function of 
millions of individuals in the US and the rest of the world.  According to the World 
Health Organization (WHO), MDD was the fourth highest cause of disability in the world 
in 2013 and is on course to be the second highest by the end of 2020.1  While the global 
lifetime incidence of MDD has been estimated to be between 15 to 20%, there was a 10-
year prevalence rise from 6.6% in 2005 to 7.3% in 2015.1, 2  The incidence of MDD 
among the general population is based on a variety of demographic, socioeconomic, and 
lifestyle factors.  Research has also revealed that depression is two to three times more 
common in individuals who already have multimorbidities compared to those with one or 
no chronic physical conditions.3  This data indicates a potential risk for a cyclical or 
synergistic pattern of depression and chronic disease, due to the inflammatory effect that 
depression has on human physiology. 
With research indicating that diet, sleep, and exercise all have a significant impact 
on the development, progression, and management of depression, there is an opportunity 
for creating non-pharmacological interventions that address these factors, especially 
among those individuals not currently following any treatments for depression.4  To date, 
most research examining how nutrition can improve mental health has utilized dietary 
interventions that emphasize a higher intake of fruits, vegetables, and whole grains, 




unsaturated fats, or limiting the consumption of foods that are highly processed or contain 
high amounts of added sugars.5  However, with the continued rise in the prevalence of 
MDD, it would be beneficial to continue research into the effects of nontraditional dietary 
interventions that do not necessarily strictly follow to these typical eating patterns.  
Therefore, this narrative review will describe the pathophysiology of MDD, including 
brain nutrient metabolism and oxidative stress, and the relationship between MDD and 
obesity.  Additionally, it will review current research regarding the high-fat, low-
carbohydrate ketogenic diet and its mechanistic action on neurophysiological systems 
that are dysregulated in MDD to outline the therapeutic potential of this type of dietary 
intervention in the treatment of the condition.  
METHODS 
 An initial literature search was conducted between February 5, 2018 and May 4, 
2018, in addition to an updated search between March 2, 2020 and June 5, 2020, using 
three databases.  The databases (PubMed, Cumulative Index to Nursing and Allied Health 
Literature [CINAHL], and Cochrane Library) were searched using the following terms 
either singularly or in combination: Ketogenic Diet, Ketone Metabolism, Major 
Depressive Disorder or Depression, Brain-derived Neurotrophic Factor, Oxidative 
Stress, and Obesity.  The review includes intervention studies with no restrictions on the 
population examined but is limited to research published after January 1, 2000 and 
written in the English language.  Articles were excluded if the primary dietary 
intervention utilized a low carbohydrate non-ketogenic diet or exogenous ketone source, 
or if the sample size was less than 50 human participants.  The research design was not a 




control groups within the reviewed studies.  Figure 1 summarizes the processes of this 
literature search, and Table 1 presents a summary of the literature. 
 
DISCUSSION 
Neuropathology of Major Depressive Disorder 
To better comprehend the prevalence and effects of MDD, it is important to 
understand its status as a mental health condition and how it is categorized and diagnosed 
by mental health professionals.  MDD is classified as a neuropsychiatric mood disorder 




activities.6  A diagnosis typically designates the condition as either an isolated or 
recurrent episode, and will classify the episode as mild, moderate, or severe.6  MDD is 
considered to be caused by a combination of various biological, psychological, and social 
stressors, which can create an inflammatory state within the body that affects multiple 
physiological organ systems.  These factors can also alter some of the major brain 
functions including brain glucose metabolism, regulation of brain-derived neurotrophic 
factor (BDNF), and antioxidant activity. 
 Glucose metabolism.  Although glucose is typically the main source of energy 
for the brain, there are significant alterations in the mechanisms of glucose metabolism in 
populations affected by major depression.  Several studies examining individuals with 
MDD have demonstrated regional glucose hypometabolism and metabolic asymmetry in 
various regions of the brain, including the left prefrontal cortex, cerebellum, left anterior 
cingulate, right insular cortex, right claustrum, right anteroventral caudate and putamen, 
right middle temporal gyrus, and right superior temporal gyrus.7-9  These alterations have 
been associated with the progression of depressive episodes as individuals with more 
severe depression have demonstrated lower global cerebral glucose metabolic rates.10  It 
has also been shown that successful pharmacological treatment with various 
antidepressants can increase glucose utilization in the left prefrontal cortex; although, this 
may not improve whole frontal glucose metabolism.8  Holthoff et al. even reported 
decreases in regional glucose metabolism in remitted MDD patients treated with selective 
serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors 
(SNRIs).7  These results demonstrate that specific antidepressant treatments may not 




metabolism.  A possible causal link between MDD and decreased cerebral glucose 
metabolism was illustrated by Kahl et al. showing that elevated DNA methylation of 
GLUT1 in unremitted MDD patients lowered GLUT1 expression in brain cells, but could 
be reversed through MDD remission.11  These findings indicate that glucose uptake from 
blood vessels into the brain may be compromised in both untreated and treated MDD and 
suggest that the utilization of other energy sources could potentially improve cerebral 
metabolism for these individuals. 
 BDNF.  Although brain metabolic dysfunction is an important factor in the 
pathophysiology of depression, there are other noted alterations in brain function, such as 
changes to the activity of BDNF.  BDNF is the most abundant neurotrophin in the 
nervous system and is involved in the development and regulation of neuronal systems, 
neurotransmitter activity, and neuroplasticity.12, 13  Individuals with MDD have been 
shown to have significantly lower concentrations of serum BDNF in comparison to 
healthy controls.12, 14-19  Lower serum BDNF levels have also been reported during 
recurrent depressive episodes as compared to first episodes,14 in individuals with long-
term MDD (≥1 year) as compared to short-term MDD (<1 year),20 and in individuals with 
MDD as compared to individuals with dysthymia.17  Sözeri-Varma et al. did find one 
contrasting result by demonstrating that there was no significant difference in serum 
BDNF levels between individuals in their first and recurrent MDD episodes.15  Regarding 
the correlation between MDD treatment and BDNF activity, it has been demonstrated 
that antidepressants can increase serum BDNF levels in individuals with MDD.12, 16, 19  
While these findings do not indicate that antidepressants only treat MDD by improving 




pathophysiology of MDD and other affective disorders.12, 16, 19 Although most data 
appears to support this hypothesis, there is no evidence for directionality in this 
relationship, and some conflicting data has been shown between serum BDNF levels and 
the severity of MDD.14, 15, 20  The correlation between improvements to reduced BDNF 
levels and the severity of MDD symptoms warrants additional research, especially 
regarding treatments and interventions that can improve both of these conditions. 
 Oxidative Stress.  Other prevalent alterations to brain function in MDD can 
occur through the action of oxidative stress, which can have significant effects on brain 
structure and metabolism, and neuronal interaction.  Markers of oxidative stress and 
reduced antioxidant function have been repeatedly noted in individuals with MDD 
compared to healthy controls.21-25  The major brain antioxidant glutathione, its 
complementary enzyme glutathione peroxidase (GPx), and the detoxifying brain isozyme 
glutathione S-transferase Mu 1 (GST Mu 1) were shown to be significantly lowered in 
post-mortem brain tissues of individuals with MDD, bipolar disorder, and 
schizophrenia21, 26 and the serum of living individuals with MDD.22, 25  However, there 
has been a report that found no difference in GPx activity between individuals with MDD 
and healthy controls.23  While these enzymes are typically reduced during MDD, there 
have also been some reports of increased activity of the antioxidant enzymes glutathione 
reductase,22, 26 superoxide dismutase (SOD),22, 26, 27 and catalase.23, 27  However, Rybka et 
al. did find decreased SOD activity in individuals with MDD in comparison to healthy 
controls.25  Additionally, some of these antioxidant activities have not been shown to 
improve or have been slightly suppressed with the pharmacological treatment of MDD.23, 




MDD, is likely exacerbated by antioxidant dysregulation and dysfunction.  Markers of 
oxidative stress, such as malondialdehyde, 8-OH 2-deoxyguanosine, interleukin-6, tumor 
necrosis factor-α (TNF-α), F2-isoprostanes, neopterin have also been found in elevated 
levels in individuals with MDD, and some have been associated with decreased 
effectiveness of antidepressant treatments.24-26  Interleukin-6 levels, however, have been 
shown to decrease with SSRI treatment.24  The relative ineffectiveness of several 
antidepressant treatments for improving oxidative stress in MDD suggests that other 
therapeutic methods should be examined for the limitation of prooxidant and 
enhancement of antioxidant systems. 
 Obesity.  Due to its similar relationship with increased oxidative stress and 
systemic inflammation, it is important to also examine obesity and how it correlates with 
MDD.  There have been numerous large-scale, cross-sectional epidemiological and 
observational studies that have examined this relationship, and have demonstrated a 
positive correlation between obesity and MDD.28-32  Several studies have reported that 
this association occurs mainly between MDD and severe or class III obesity (body mass 
index ≥ 40 kg/m2).28, 33, 34  Despite this significant correlation, no causal direction of the 
MDD-obesity relationship has been officially established. It has been shown that the 
presence of overweight or obesity in individuals with MDD can significantly slow their 
clinical and neuroendocrine responses to antidepressant treatment.35 Additionally, weight 
loss has been associated with a significant, sustained reduction in the severity of MDD, 
with individuals achieving greater weight loss also experiencing the largest reduction in 
MDD severity.34   The importance of treating MDD is further emphasized by the 




obesity, and an increased risk for the development of other psychiatric disorders, 
smoking, physical inactivity, alcohol and substance abuse, disordered eating, and other 
unhealthy behaviors.28, 30  Although these findings did not determine a specific causal 
direction in the MDD-obesity relationship, they do suggest the dire need for a 
multifactorial and comprehensive approach to the treatment of MDD and obesity, beyond 
pharmaceuticals, especially when the conditions are concurrently present. 
Effects of a Ketogenic Diet on Neurophysiology 
 Traditional treatments for MDD may not always be effective in managing 
physiological consequences of the condition, especially reduced glucose metabolism in 
the brain, decreased BDNF levels, increased levels of oxidative stress, or comorbid 
chronic diseases. A possible alternative or complementary treatment for MDD would be a 
dietary intervention focusing on the ketogenic diet, which is a high-fat, very low-
carbohydrate, adequate-protein eating plan.  Typically, it includes an initial reduction of 
net carbohydrate intake to less than 20-50 grams per day with a macronutrient 
distribution of approximately 0-10% carbohydrate, 60-80% fat, and 10-30% protein as a 
percent of total energy intake.36  This severe restriction of carbohydrates imitates a 
“fasted state” by lowering glucose availability, which decreases insulin and increases 
glucagon concentrations and creates a metabolic shift in the body from fat storage to 
lipolysis and β-oxidation.37  However, in the ketogenic diet, both exogenous and 
endogenous protein and fat sources can provide energy, and glucose concentrations can 
be relatively maintained without carbohydrate intake.36  The ketogenic diet’s alternative 
nutrient utilization is one of its most important characteristics and may be beneficial for 




The subsequent sections describe the mechanisms of action related to the ketogenic diet 
in brain nutrient metabolism, the production of BDNF, regulation of oxidative stress, and 
weight management that could improve some of the other physiological consequences of 
MDD. 
 Ketone Metabolism. As the ketogenic diet restricts carbohydrate intake to a level 
at which the body is not able to maintain carbohydrate utilization throughout all tissues, it 
is necessary that the body more effectively use lipids and their metabolites for energy.  
When energy is mainly provided by fatty acid oxidation in cell mitochondria, large 
amounts of acetyl-CoA are produced, which are then utilized, primarily in the liver, to 
synthesize the ketone bodies β-hydroxybutyrate (β-HB), acetoacetate and acetone.38  
Ketosis occurs when the metabolic efficiency of the Krebs, or tricarboxylic acid (TCA) 
cycle, is reduced and additional acetyl-CoA is converted into ketones.38  Because the 
liver does not have succinyl CoA:3- ketoacid CoA transferase, a mitochondrial enzyme 
that converts acetoacetate to acetoacetyl CoA, ketone bodies are forced into the 
circulatory system.39  In ketosis, the levels of the ketone bodies β-HB, acetoacetate, and 
acetone are increased in the peripheral blood and urine.  These ketones are delivered to 
and serve as a fuel source for numerous extrahepatic tissues, including the brain.38, 40  
Higher levels of ketosis will proportionally spare glucose from metabolism in the brain 
and other tissues.40   This mechanism has great significance in conditions in which 
glucose availability can be severely limited, as fatty acids are not able to cross the blood-
brain barrier to provide energy.  This sparing effect of ketones for glucose in cerebral 
metabolism has been shown in rat models and has demonstrated a coordinated 




To the knowledge of the researchers, no current research has demonstrated these findings 
in any human population.  Despite this lack of research, the ketogenic diet provides an 
alternative source of energy for the brain, which could benefit individuals with MDD 
who experience significantly reduced brain glucose metabolism. 
 BDNF Activity and the Ketogenic Diet.  Another aspect of brain function 
affected by ketone bodies is the concentration and activity of BDNF.  Although no 
studies have demonstrated in vivo action of ketones on the expression of BDNF in 
humans, in vivo and vitro animal models have shown ketone-mediated alterations in 
BDNF gene expression and protein levels.42-44  Genzer et al. showed an increase in the 
BDNF:proBDNF ratio, whole brain and liver BDNF expression, and BDNF mRNA in a 
population of C57BL/6 male mice fed an ad libitum ketogenic diet.42   This finding 
suggests a ketone-induced upregulation of BDNF production, especially in the brain.  
However, Vizuete et al. demonstrated that BDNF content was decreased in the corpus 
striatum, but not the hippocampus, in male Wistar rats fed a ketogenic diet.44  These 
conflicting results imply that a ketogenic diet may affect BDNF regulation by increasing 
total BDNF gene expression and content but reducing regional BDNF synthesis.  In an in 
vitro study of exercised male C57BL/6 mice, β-HB was found to increase with exercise 
and coincided with an increase in BDNF expression and protein levels in cortical 
neurons.43  This finding is consistent with the results of the previously discussed in vivo 
studies, as it suggests that β-HB is involved in the in vivo regulation of BDNF.  Although 
these studies have only examined animal models, they indicate that there could be 
benefits of using a ketogenic diet in conditions like MDD, in which BDNF expression or 




 Oxidative Stress and the Ketogenic Diet.  In addition to the previously 
mentioned metabolic and neurological alterations, the ketogenic diet has been shown to 
have significant impacts on both systemic and brain oxidant-antioxidant systems.  The 
theorized neuroprotective effect of the ketogenic diet is associated with acetoacetate and 
β-HB and has only been demonstrated in animal models.  These studies have shown that 
a ketogenic diet, via acetoacetate and β-HB action, can protect hippocampal and 
dopaminergic neurons from glutamate-induced or 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) excitotoxicity and can increase glutathione synthesis and 
NAD(P)H dehydrogenase quinone 1 (NQO1) activity.45-47  The upregulation of these 
antioxidant substrates could contribute to the ketogenic diet’s protective mechanism 
against oxidative damage and improvements in mitochondrial redox status.  An animal 
study showed the indirect effects of the ketogenic diet in mediating oxidative stress by 
decreasing the production of reactive oxygen species (ROS) and increasing gene 
expression of cytosolic and mitochondrial antioxidants.47, 48  It is suggested that the 
reduction in ROS production is achieved by improving mitochondrial uncoupling protein 
activity, which reduces the membrane potential upon which the ROS production is 
dependent.48  The ketogenic diet has also been shown to improve hippocampal 
mitochondrial antioxidant capacity, specifically by increasing NQO1, SOD, and GPx 
expression and decreasing catalase activity in animal models.49, 50  These animal-based 
studies demonstrate that the ketogenic diet has the potential for reliable antioxidant, anti-
inflammatory, and neuroprotective capabilities in conditions, like MDD and obesity, that 




However, more research is needed to determine if the ketogenic diet can reliably improve 
antioxidant capacity and reduce oxidative damage in humans. 
 Mood Changes with the Ketogenic Diet.  Several animal studies have 
demonstrated possible antidepressant or mood-improving properties of the ketogenic diet; 
however, the exact mechanisms have not been established. One of these studies appeared 
to show that a ketogenic diet, mainly through the action of β-HB, reduced “behavioral 
despair”  in stressor-exposed male Wistar rats.51  Another animal study examined the 
offspring of female CD-1 mice that had followed a ketogenic diet during gestation and 
found that prenatal exposure to a ketogenic diet altered the offspring’s neuroanatomy and 
improved their resistance to the development of anxiety and depression in adulthood.52  
The primary changes to neuroanatomy in these offspring compared to controls were 
increased cerebellar volume and a reduction in the hypothalamic and corpus callosum.  A 
study conducted in a human sample by Halyburton et al. compared the effects of a low-
carbohydrate ketogenic diet to a high-carbohydrate diet on mood and cognitive 
performance.53  These researchers showed that both diets were effective in improving 
mood, with no difference in effectiveness, but that the low-carbohydrate ketogenic diet 
improved cognitive processing speed more than the other dietary intervention.  However, 
the generalizability of this study is limited to “healthy, overweight and obese, young to 
middle-aged adults with normal mood state and no cognitive impairment”, and not 
populations with diagnosed MDD.53 Further research is warranted to determine the 
influence of the ketogenic diet on improving characteristics of mood that are specifically 




 Obesity and the Ketogenic Diet.  While the primary purpose of this narrative 
review is to outline the therapeutic potential of a ketogenic diet in treating MDD, it also 
seeks to confirm previously demonstrated effects of the ketogenic diet on body 
composition, especially in overweight and obese populations.  Because of the elevated 
risk for these populations to develop MDD, other psychiatric disorders, and chronic 
metabolic diseases, it would be beneficial to identify treatments that can improve 
conditions that affect both mental and metabolic health.  Within the literary body of 
evidence, there is varying data regarding the effectiveness of the low-carbohydrate or 
ketogenic diets in comparison to other traditional weight-loss dietary interventions.  
Several studies of the ketogenic diet have demonstrated significantly greater 
improvements in weight loss and reductions in abdominal and visceral obesity in 
comparison to low-fat diets.54-56  In contrast to this data supporting the efficacy of the 
ketogenic diet, numerous studies also demonstrate that while the ketogenic diet does 
induce weight loss, the diet’s effect is no different than that of a low-fat diet for the 
treatment of obesity.57-62  The primary theory for the ketogenic diet having no greater 
effectiveness than other traditional weight-loss diets is that all weight-loss diets have 
relatively similar total energy intakes and that there is no metabolic advantage to one or 
more particular macronutrients. The correlation between MDD and obesity supports 
further research into and the utilization of therapies like the ketogenic diet that can 
improve both conditions through multiple physiological mechanisms.  
 Biomarker Alterations with the Ketogenic Diet.  The association between 
biomarkers such as serum lipids and glucose and the oxidative stress and inflammation 




However,  the evidence for the impact of a ketogenic dietary intervention on these 
biomarkers is highly ambiguous.  Based on numerous studies examining the use of the 
ketogenic diet for weight-loss intervention and improvement of metabolic risk factors, it 
has been shown that the ketogenic diet has more significant effects on lipid profiles, 
glycemic control, and insulin resistance compared to traditional weight-loss diets.  Some 
studies have shown a serum lipid response to a ketogenic diet that includes an increase in 
low-density lipoprotein (LDL),54, 57, 60, 61 an increase in high-density lipoprotein (HDL),54, 
57, 60-63 and a decrease in triglycerides (TG).54, 56, 57, 59-62  Other studies have shown 
different effects on serum lipids leading to unchanged or decreased HDL,59 total 
cholesterol,56, 59, 62, 63 and LDL.56, 59, 62, 63  Alterations to glycemic control typically show 
decreased serum glucose,58, 60-63 decreased insulin,60, 61 and decreased insulin resistance.58, 
63   These biomarkers are an important indicator of health as they are correlated with 
chronic stress and inflammation that can lead to the development of comorbid metabolic 
and psychiatric conditions.  Based on the research regarding the influence of the 
ketogenic diet on metabolic biomarkers, the ketogenic diet may be beneficial for 
individuals with issues of glycemic control; however, there is no consensus regarding 
improvements to lipid markers as an effect of the ketogenic diet.  Further research could 
provide valuable data to this area of literature, specifically by examining the effects of the 
ketogenic diet on these biomarkers in populations with MDD and other mood disorders. 
CONCLUSIONS 
 
 This narrative review illustrates that MDD is a prevalent health condition that in 
addition to adverse mood and behavioral changes, results in numerous physiological 




diseases.  It is of vital importance to develop novel therapies that have the potential to 
utilize multiple mechanisms of action to treat this condition with long-term success.  The 
ketogenic diet is a specific intervention that could prove effective in reducing the severity 
of depression, improving body composition, and attenuating the effects of several chronic 
diseases.  Although the ketogenic diet has been shown to have varying effects on mood in 
humans, animal models show promise in the use of this diet as nutrition therapy for MDD 
through alternate nutrient utilization of lipid metabolites, increased BDNF activity, and 
improved antioxidant capacity in the brain.  The current state of literature presents an 
opportunity for psychology and nutrition researchers to progress from animal models to 
examine whether these effects are observable in a human population while assessing 
mood state and psychological characteristics of MDD.  
 The ketogenic diet may be beneficial for other diseases or disorders in which 
improvements in systemic inflammation also reduce the severity of the condition. The 
research concerning the effectiveness of the ketogenic diet for body composition 
improvement consistently demonstrates that the diet induces total weight and fat mass 
loss; however, conflict in the literature does exist as to whether the ketogenic diet is more 
effective than traditional weight-loss dietary interventions in the short- and long-term, 
and as to which populations would benefit from its implementation.  As the ketogenic 
diet has rarely been shown to be less effective, it has potential use for populations with all 
levels of overweightness and obesity, although concerns with adherence and 
sustainability of this dietary pattern do exist.  This narrative review has also demonstrated 
that the ketogenic diet can improve biomarkers of glycemic control and inflammation; 




cardiovascular disease.  Future research should continue to examine the nutritional 
consequences of the ketogenic diet through the analysis of changes to metabolic 
biomarkers. 
 The potential physiological outcomes of the ketogenic diet support its application 
in research for populations that are at risk for or have comorbid psychological and 
metabolic conditions.  Integration of the ketogenic diet into other lifestyle improvement 
and weight loss strategies may prove particularly effective for these populations as 
multifactorial approaches are more effective for treating comorbid conditions that affect 
multiple physiological systems.  However, future research first needs to employ 
randomized controlled trials to thoroughly examine the short- and long-term 
psychological, physiological, and metabolic effects of a ketogenic diet in a population 
with MDD.  These studies should consider possible confounding variables, such as 
psychiatric and metabolic comorbidities, previous antidepressant treatment, race and 
ethnicity, sex and gender, age, and previous use of other nutrition therapies.  If the 
ketogenic diet proves to be safe, reliable, and effective as a nutrition therapy for MDD, 
further research could explore the different responses to the ketogenic diet based on the 
severity of MDD and length of the episode or history of recurrence, and should include a 
long-term follow up to assess the sustainability of these desire outcomes.  Although 
further research is warranted before nutrition therapy recommendations can be 
established, both mental health and nutrition professionals should consider the 
therapeutic potential of the ketogenic diet for individuals with MDD or multimorbidities 






Table 1. Studies investigating the ketogenic diet and characteristics of MDD 




RCT 148 adults 
Ages 22-75 y 
BMI 30-45kg/m2 
12-months diet 
Low carbohydrate diet (LCD): < 
40 g carbohydrate / day 
Low Fat diet (LFD): < 30% of total 




Serum high-density lipoprotein (HDL) 
Serum Triglycerides (TGs) 
Plasma glucose 
Serum C-reactive protein (CRP) 
LCD group experienced greater weight loss 
Fat mass decreased more in the LCD group 
HDL was increased more in  the LCD group 
TGs were decreased more in the LCD group 
Plasma glucose was not changed for either 
group 




RCT 57 male Sprague-
Dawley rats, ~40 days 
old 
3-week diet 
Kcal-restricted Ketogenic diet 
(KD): BioServ F3666 
Normal,	ad	libitum	control	diet	
(Purina	5001) 
Plasma Beta-hydroxybutyrate (β-HB) 
Plasma glucose  
Cerebral metabolites and nucleotides 
Enzyme activity 
Mitchondrial count 
KD was associated with upregulation of 
metabolic gene transcripts (protein metabolism, 
glycolysis, tricarboxylic acid, oxidative 
phosphorylation) 
No difference in activity of energy metabolic 
enzymes between groups 
KD was associated with an increased number of 
mitochondrial profiles in the hippocampus 
KD was associated with hippocampal synaptic 





RCT 107 adults 
Ages 18-65y 
Abdominal obesity and 
one metabolic 
syndrome risk factor 
 
12-month diet 
Isocaloric diets with mild kcal 
restriction: 1430 kcal for females, 
1675 kcal for males 
Very low carbohydrate diet 
(VLCD; 4% carbohydrate, 35% 
protein, 61% fat/20% saturated fat) 
Low fat diet (LFD; 46% 
carbohydrate, 24% protein, 30% 
fat) 
Body weight 
Fat mass (FM) 
Fat-free mass (FFM) 
Plasma glucose 
Serum total cholesterol (TC) 
Serum High density lipoprotein (HDL) 
Serum Low density lipoprotein (LDL) 
Serum Triglycerides (TGs) 
Blood glucose  
Both diets resulted in weight loss and a 
decrease in FM, with no differences between 
groups 
VLCD was associated with greater decrease in 
FFM than the LFD 
Blood glucose was decreased in both groups 
TC, LDL, HDL were increased more in the 
VLCD group 






83 obese (39 males, 44 
females) 
BMI > 35 kg/m2 
 
24-week ketogenic diet 
First 12 weeks: 20-30g total 
carbohydrate and 80-100g protein, 
emphasis on poly- and 
monounsaturated fats for fat intake 
Second 12 weeks: increase to 40-
50 g carbohydrate  
Daily multivitamin/mineral 
Body weight/BMI 
Serum total cholesterol (TC) 
Serum High density lipoprotein (HDL) 
Serum Low density lipoprotein (LDL) 
Serum Triglycerides (TGs) 
Blood glucose 
Body weight decreased during all stages of diet 
TC, LDL, and TGs decreased from baseline to 
post-test 
HDL increased from baseline to post-test 
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RCT 61 adults 
Ages 18-50y 
BMI 28-40kg/m2 
Insulin resistant (IR) or 
sensitive (IS) 
6-month diet 
Low Fat diet (LFD): 20 g fat / day 
Low Carbohydrate diet (LCD): 20 
g digestible carbohydrate/ day  
4 groups: LFD-IR, LFD-IS, LCD-
IR, and LCD-IS 
Body weight change 
Plasma High density lipoprotein 
(HDL) 
Plasma Low density lipoprotein (LDL) 
Plasma Triglycerides (TGs) 
 
All diets experienced weight loss, but there was 
no difference between groups 
LDL decreased in both LFD groups, and 
increased in both LCD groups 
TGs decreased for all groups, but there was no 
difference between groups 
HDL increased for all groups, but there was no 
difference between groups 
Fasting glucose decreased for three groups, but 
not the LCD-IS group, and there was no 




RCT 96 C57BL/6 male mice, 
4wk old 
2-week Ad libitum low-fat diet 
(LFD) 
6 groups: 8-week ad libitum LFD, 
restricted feeding LFD (RF-LFD), 
high fat diet (HFD), RF-HFD, 
ketogenic diet (KD), or RF-KD 
BDNF mRNA expression HFD was associated with increases in brain and 
liver BDNF expression 
KD was associated with increases in 
BDNF:proBDNF ratio, whole brain and liver 





RCT 36 male Sprague-
Dawley rats 
35 days old 
6-24hours diet 
Ketogenic diet (8.4% protein, 
78.8% fat, 0.8% carbohydrate, 5% 
fiber) 
Standard diet (18.6% protein, 6.2% 
fat, 59.8% carbohydrate, 4.8 fiber) 
Controlled cortical impact (CCI) 
surgery or placebo 
3-nitrotyrosine (3NT) 
4-hydroxynonenol (4-HNE)  
expression 
NAD(P)H dehydrogenase quinone 1 
(NQO1) expression 
Superoxide Dismutase (SOD1 and 2) 
expression 
Ketogenic diet was associated with decreased 
3NT expression and increased 4HNE, NQO1 
and SOD1 expression 
Ketogenic diet was associated with an increase 
in protein expression of cytosolic and 
mitochondrial antioxidants 
Ketogenic was associated with a decrease in 




RCT 121 adults, overweight 
or obese 
Age 24-64 y 
BMI 26-43 kg/m2 
8-week diet 
Low Carbohydrate High Fat 
(LCHF) diet (35% protein, 61% 
fat, 20% saturated fat, 4% 
carbohydrate) 
High Carbohydrate Low Fat 
(HCLF) diet (24% protein, 30% 
fat, <8% saturated fat, 46% 
carbohydrate) 
Both diets isocaloric and with 30% 
energy requirement restriction 
Beck Depression Inventory (BDI) 
Profile of Mood States (POMS) 
Spielberger State Anxiety Inventory 
(SAI) 
Cognitive function: digit span 




LCHF diet was associated with an increase in 
plasma ketones 
LCHF diet group experience greater weight loss 
than the HCLF diet group 
Both diets should a significant improvement in 
BDI, POMS, and SAI scores, but there was no 
difference between groups 
DSB scores increased in both groups 









Ketogenic diet (Bio-Serv F3666) 
Control Diet (Bio Serv F3517) 
Diets were isocaloric and 90% of 
daily requirements 
Serum Β-HB 
Glutathione (GSH) concentration 
Reduced coenzyme A (CoASH) levels 
Glutamate cysteine ligase (GCL) levels 
Ketogenic diet was associated with an 
upregulation of GSH synthesis 
Ketogenic diet was associated with an increase 
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RCT 104 adults 
1 or more 
cardiovascular disease  
risk factor 
BMI 28-40 kg/m2 
15-month diet: 3 months with 
counseling, 12 months self-
maintenance 
All diets 1550kcal 
Very Low Carbohydrate (VLC; 
35% protein/60% fat/20% 
saturated fat/4% carbohydrate) 
Very Low Fat (VLF; 20% 
protein/10% fat /3% saturated fat 
/70% carbohydrate) 
High Unsaturated Fat (HUF; 20% 
protein/ 30% fat/ 6 saturated 




Blood pressure (BP)  
Serum High density lipoprotein (HDL) 
Serum Low density lipoprotein (LDL) 
Serum Triglycerides (TGs) 
Blood glucose 
Plasma ketones 
All diets, excluding control, experienced weight 
loss with no differences between groups 
VLC was associated with increases in LDL and 
HDL, while other diets decreased both factors 
VLC was associated with a decrease in TGs, 
while other diets increased this factor 
All diets, excluding control, experienced a 





RCT 16 male C57BL/6 mice 6-week diet 
2 groups: with (n=8) and without 
(n=8) running wheels 
Food and water ad libitum 
12h light/12h dark cycle 
Plasma 3-hydroxybutyrate (3-HB) 
concentration 
Neuronal oxygen consumption and 
glycolytic rate 
Neuronal BDNF concentrations 
Higher 3-HB concentrations were associated 
with increases in neuronal oxidative 
metabolism and metabolic rate Higher 3-HB 
concentrations were associated with increased 
ATP production, NAD/NADH ratio, and 
mitochondrial electron transport chain activity 
Higher 3-HB concentrations were associated 
with increased  BDNF mRNA and protein 




RCT 12 male Sprague-
Dawley rats 
1-, 3-day or 1- or 3-week diets 
12h light/dark cycle 
Water ad libitum 
Fasted 8-10 hours pre-diet 
Ketogenic diet (78% F, 0.76% C) 
or control (5% F, 65% C) 
kcal restrict to 90% daily 
requirements 




Reduced coenzyme A (CoASH) 
Ketogenic diet was associated with increased 
hippocampal GSH synthesis and NQO1 activity 
Ketogenic diet was associated with decreased 




RCT 40 adult male Wistar 
rats 
 
7 day diet 
2 groups: Ketogenic diet (n=20) 
and control (n=20) 
Food access 2.5 hours per day 
Serum Β-HB 
Porsolt Test: animal model of 
depression  
Ketogenic diet was associated with an increase 
in serum Β-HB 
Ketogenic diet was associated with better 
performance on the Porsolt test, indicating less 
behavioral despair 
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RCT 67 adults 
One or more 
cardiovascular risk 
factor BMI > 28 kg/m22 
 
12-week diet: 8-week intervention 
and 4-week weight maintenance 
Isocaloric diet 1450kcal 
Very Low Fat (VLF) 
(Carbohydrate%: Fat%: Protein%, 
%SF = 70:10:20; 3%) 
High Unsaturated Fat (HUF) = 
(50:30:20, 6%) 





Serum total cholesterol (TC) 
Serum High density lipoprotein (HDL) 
Serum Low density lipoprotein (LDL) 
Serum Triglycerides (TGs) 
Blood glucose 
Fasting insulin 
All groups experienced weight loss and lean 
mass loss, but there was no difference between 
groups 
All groups experience fat mass loss, but the 
VLC and VLF groups experienced greater 
reductions 
LDL and HDL were increased more in the VLC 
group compared to the other groups 
TGs were decreased in the VLC group 
compared to other groups 
Blood glucose did not change for any groups 
Fasting insulin was decreased more in the VLC 




RCT 132 adults 
Severely obese (BMI > 
35kg/m2) 
6-month diet 
Low carbohydrate diet (LCD): < 
30 g CHO/day, no restriction on fat 
intake 
Low fat diet (LFD): 500 kcal 
deficit, < 30% kcal from fat 
Body weight 
Serum Triglycerides (TGs) 
Serum High density lipoprotein (HDL) 
Serum Low density lipoprotein (LDL) 
Fasting blood glucose 
LCD was associated with greater weight loss 
compared to the LFD 
TGs were decreased more in the LCD diet 
Neither experienced a significant change in 
HDL or LDL 
Glucose levels were only significantly 





RCT 87 adults 
Severely obese (BMI > 
35kg/m2) 
1-year follow-up 
Low carbohydrate diet (LCD): < 
30 g CHO/day, no restriction on fat 
intake 
Low fat diet (LFD): 500 kcal 
deficit, < 30% kcal from fat 
Body weight 
Serum total cholesterol (TC) 
Serum High density lipoprotein (HDL) 
Serum Low density lipoprotein (LDL) 
Serum Triglycerides (TGs) 
Blood glucose 
HbA1c 
Both groups experienced weight loss but there 
was no difference between groups 
Changes in total cholesterol and LDL were not 
different between baseline and follow-up or 
between groups 
TGs decreased more in the LCD group 
HDL decreased in both groups, but was reduced 
more in the LFD group 
Changes in blood glucose were not different 
between baseline and follow-up or between 
groups 
HbA1c was lower for the LCD group only for 




RCT 45 C3HeB/FeJ mice 10-12 day diet 
Ketogenic diet (Bio-Serv F3666) 
(n=22) 
Standard diet (n=23) 
Food and water ad libitum 
Serum Β-HB 
Hippocampal mitochondrial respiration 
and Reactive Oxygen Species (ROS) 
production 
Ketogenic diet was associated with an increase 
in serum Β-HB levels 
Ketogenic diet was associated with an increase 
in hippocampal mitochondrial respiration rate 
Ketogenic diet was associated with decreased 
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RCT 24 Male and female 
CD-1 parental mice 
44 6-weeks old 
offspring mice 
 
30-day diet for parent mice 
KD (67.4% fat, 0.6% carbohydrate, 
and 15.3% protein) or control (5% 
fat, 76.1% carbohydrate, and 
18.9% protein) 
Ad libitum food and water 
Males and female naturally mated 
after diet ended 
Ketogenic diet (n=20) and  control 
(n=24) offspring tested  
Open-field test (locomotor activity and 
anxiety model) 
Forced-swim test (behavioral despair 
model) 
Exercise-wheel test (physical activity 
model) 
Ketogenic diet was associated with reduced 
susceptibility to depression and anxiety and 
increased physical activity in offspring 
Ketogenic diet was associated with an increase 
in the volume of cerebellum and decreases in 





RCT 109 adults 
Ages 18 to 65 
Abdominal obesity and 
one or more metabolic 
syndrome risk factors 
24-week diet 
Very Low Carbohydrate High Fat 
diet (VLCHF; 4% carbohydrate, 
35% protein, 61% fat) 
High Carbohydrate Low Fat diet 
(HCLF; 46% carbohydrate, 24% 
protein, 30% fat (< 8% sat fat); 
<10g/d saturated fat 
Both diets restricted to 1430 kcal 
for women and 1670 kcal for men 
Body weight 
Serum total cholesterol (TC) 
Serum High density lipoprotein (HDL) 
Serum Low density lipoprotein (LDL) 
Serum Triglycerides (TGs) 
Blood glucose 
C-reactive Protein (CRP) 
Both diets resulted in weight loss, with no 
differences between groups 
Total cholesterol and LDL decreased in the 
HCLF group, but did not change in the VLCHF 
group 
HDL increased in both groups, but was higher 
in the VLCHF group 
TGs decreased in both groups, but were 
reduced more in the VLCHF group 
Fasting glucose and CRP decreased in both 





RCT 60 male Wistar rats, 30 
days old 
8-week diet 
3 groups: control (n=20), standard 
ketogenic diet (n=20), enriched 
omega-3 ketogenic diet (n=20) 
12h light/dark cycle 
BDNF concentration in hippocampi 
and corpus striatum 
Ketogenic diet was associated with decreased 
BDNF content in the corpus striatum and no 





RCT 119 overweight, 
hyperlipidemic adults 
Age 18-65 y 
BMI 30-60 kg/m2 
 
Low Carbohydrate Ketogenic Diet 
(LCKD, < 20 g carbohydrate) (n= 
59) 
Low Fat Diet (LFD, < 30% fat, 
<300mg cholesterol, 100-500 kcal 
restriction) (n=60) 
45 LCKD and 34 LFD completed 
Body weight 
Triglycerides (TGs) 
High density lipoprotein (HDL) 
Low density lipoprotein (LDL) 
 
LCKD was associated with a greater decrease 
in body weight than the LFD 
TGs were decreased more in the LCKD group 
HDL was increased more in the LCKD group 
LDL was increased in both groups, but was 
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RCT Male C57BL/6 J mice 
8 weeks old 
2-day or 1-week diet 
Standard diet(SD) and water ad 
libitum for 1-week pre-diet 
Ketogenic diet or SD groups 
With and without 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine  
(MPTP) injections (4 injections at 
2-hour intervals) 
Diets begin after injections 
Dopamine concentrations 
Proinflammatory cytokine levels 
(Interleukin-1Beta, Interleukin-6, 
Tumor Necrosis Factor-alpha) 
Ketogenic diet protected dopaminergic neurons 
against MPTP-induced degradation 
KD inhibited increase of proinflammatory 




RCT 19 male Wistar rats, 40 
days old 
4-week diet: 1-week acclimation, 
3-week intervention, ad libitum 
feeding 
Ketogenic diet (KD) 
Standard diet (SD) 
 




Blood ketones (Beta-hydroxybutyrate 
and acetoacetate) 
No differences in plasma glucose between 
groups after feeding 
Plasma ketones higher and plasma lactate were 
lower in KD group than SD group 
CMR-glu was decreased in left and right 
cerebral hemispheres and cerebellum in KD 
group 
CMR-glu was lower in both hemispheres than 




RCT 20 Male Wistar rats, 
30 days old 
 
8-week diet 
Ketogenic diet or standard 
laboratory diet 
Food and water ad libitum 
Thiobarbituric Acid Reactive 
Substances (TBARS) assay 
Total Antioxidant Reactivity (TAR) 
assay 
Catalase(CAT) assay 
Superoxide dismutase (SOD) assay 
Glutathione peroxidase (GPx) assay 
TBARS levels (lipoperoxidation) was increased 
in cerebellum of ketogenic diet rats 
TAR (antioxidant capacity) was increased in 
hippocampus and decreased in cerebellum of 
ketogenic diet rats 
In hippocampus, CAT activity decreased ~50% 
and GPx activity increased ~400% in ketogenic 
diet rats 
Ketogenic diet may have neuroprotective 
qualities through increases in antioxidant 
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Subject: If You Are a Veteran, This Exciting Nutrition Study May Be For YOU! 
 
Are you ready improve your overall health? Do you want a free nutrition consultation and a 
personalized diet plan? Do you want free body composition testing and analysis? Do you want 
free assessment of your blood glucose and a full lipid profile? 
 
By participating in our study, you will have access to both a registered dietitian and fitness 
professional and receive a comprehensive health and nutrition assessment during the course of the 
study.  Additionally, if you successfully complete the study, you may eligible to receive a new 
FitBit Charge 2. 
 
Our names are Dr. Jeremy Akers, RDN and Jordan Murrin and we are an Associate Professor and 
Graduate Student research team here at James Madison University in the Health Professions 
Department. We are conducting a research study on the effect of two dietary interventions on 
body composition and metabolic health and are looking for veterans of United States Armed 
Forces to participate. Details of the study can be found below. If you or a friend are interested in 
participating, please contact Jordan Murrin via email or telephone. 
 
Contact Information: 




Name: Dr. Jeremy Akers, PhD, RDN 
Email: akersjd@jmu.edu  
Phone: 540-568-8974  
 
Who: Any veteran of the United States Armed Forces between the ages of 18-65 years.  
 
What: Participation includes: 12 weeks of FREE nutrition consultation; FREE tests to measure 
body fat and composition, blood glucose, and full lipid profiles; and a FREE personalized diet 
plan and dietary analysis.  
  
When: February 2020 
 
Thank you, 
Dr. Jeremy Akers and Jordan Murrin 
 















Health Status Questionnaire 
 
1. Has anyone in your family had a heart attack, heart surgery, or sudden death due to 
cardiovascular disease prior to the age of 65?  (Circle one)  Yes No   
  
If yes, who? 
______________________________________________________________________________ 
How old were they? (Circle one) 54 or younger 55-59  60-64 
  
2. Date of last medical exam: _______________________ 
 





4. Please list any physical or mental health conditions for which you have been diagnosed or are 





5. Please answer the questions below related to medication use: 
 
• If yes, please fill in the medication name. 
• Indicate whether you have taken the medication for the given amount of time without any 
changes to medication type or dosage. 
 
Do you currently take any medications for any of the following conditions? 
 
Depression? ______________________  Have you taken this for ≥ 8 weeks? __________ 
 
Anxiety? ______________________  Have you taken this for ≥ 8 weeks?___________ 
 
Diabetes? ________________________  Have you taken this for ≥ 2 weeks? ________ 
 
High cholesterol? _____________________  Have you taken this for ≥ 8 weeks? ______ 
 










6. The occurrence of any of these health symptoms frequently is the basis for medical attention. 












Cough up blood      
Abdominal pain      
Low back pain      
Leg pain      
Arm or shoulder 
pain      
Chest pain      
Swollen joints      
Feel faint      
Dizziness      
Breathless on 
slight exertion      
 
 
7. Have you ever been diagnosed with any psychological disorders other than major 




If yes, please explain. 
______________________________________________________ 
 














If yes, please explain. 
______________________________________________________ 
 




If yes, please explain. 
______________________________________________________ 
 
11. Do you smoke? (Circle one)  Yes  No 
 
If yes, how many per day: 
 
Cigarettes:   1-9  10-19   20-39  40 or 
more  
 
























Adapted from: Howley and Franks. (1992). Health Fitness Instructor’s Handbook. Health Status 





Beck's Depression Inventory-II (BDI-II) 
 
Please circle the answer that most accurately applies to any symptoms that you experience. 
 
1. 
0  I do not feel sad. 
1  I feel sad 
2  I am sad all the time and I can't snap out of it. 
3  I am so sad and unhappy that I can't stand it. 
2. 
0  I am not particularly discouraged about the future. 
1  I feel discouraged about the future. 
2  I feel I have nothing to look forward to. 
3  I feel the future is hopeless and that things cannot improve. 
3. 
0  I do not feel like a failure. 
1  I feel I have failed more than the average person. 
2  As I look back on my life, all I can see is a lot of failures. 
3  I feel I am a complete failure as a person. 
4. 
  0  I get as much satisfaction out of things as I used to. 
1  I don't enjoy things the way I used to. 
  2  I don't get real satisfaction out of anything anymore. 
  3  I am dissatisfied or bored with everything. 
5. 
  0  I don't feel particularly guilty 
  1  I feel guilty a good part of the time. 
2  I feel quite guilty most of the time. 
  3  I feel guilty all of the time. 
6. 
  0  I don't feel I am being punished. 
  1  I feel I may be punished. 
  2  I expect to be punished. 
  3  I feel I am being punished. 
7. 
  0  I don't feel disappointed in myself. 
  1  I am disappointed in myself. 
  2  I am disgusted with myself. 
3  I hate myself. 
8. 
  0  I don't feel I am any worse than anybody else. 
  1  I am critical of myself for my weaknesses or mistakes. 
  2  I blame myself all the time for my faults. 
  3  I blame myself for everything bad that happens. 
9. 
  0  I don't have any thoughts of killing myself. 
  1  I have thoughts of killing myself, but I would not carry them out. 
  2  I would like to kill myself. 






  0  I don't cry any more than usual. 
  1  I cry more now than I used to. 
  2  I cry all the time now. 
  3  I used to be able to cry, but now I can't cry even though I want to.  
11. 
  0  I am no more irritated by things than I ever was. 
  1  I am slightly more irritated now than usual. 
  2  I am quite annoyed or irritated a good deal of the time. 
  3  I feel irritated all the time. 
12. 
  0  I have not lost interest in other people. 
  1  I am less interested in other people than I used to be. 
  2  I have lost most of my interest in other people. 
  3  I have lost all of my interest in other people. 
13. 
0  I make decisions about as well as I ever could. 
  1  I put off making decisions more than I used to. 
  2  I have greater difficulty in making decisions more than I used to. 
3  I can't make decisions at all anymore. 
14. 
  0  I don't feel that I look any worse than I used to. 
  1  I am worried that I am looking old or unattractive. 
2  I feel there are permanent changes in my appearance that make me look 
unattractive 
  3  I believe that I look ugly. 
15. 
  0  I can work about as well as before. 
  1  It takes an extra effort to get started at doing something. 
  2  I have to push myself very hard to do anything. 
  3  I can't do any work at all. 
16. 
  0  I can sleep as well as usual. 
  1  I don't sleep as well as I used to. 
  2  I wake up 1-2 hours earlier than usual and find it hard to get back to sleep. 
  3  I wake up several hours earlier than I used to and cannot get back to sleep. 
17. 
  0  I don't get more tired than usual. 
1  I get tired more easily than I used to. 
2  I get tired from doing almost anything. 
  3  I am too tired to do anything. 
18. 
  0   My appetite is no worse than usual. 
  1   My appetite is not as good as it used to be. 
  2  My appetite is much worse now. 
  3  I have no appetite at all anymore. 
19. 
  0  I haven't lost much weight, if any, lately. 
  1  I have lost more than five pounds. 
  2  I have lost more than ten pounds. 





  0  I am no more worried about my health than usual. 
1  I am worried about physical problems like aches, pains, upset stomach, or 
constipation. 
  2  I am very worried about physical problems and it's hard to think of much else. 
  3  I am so worried about my physical problems that I cannot think of anything else. 
21. 
0  I have not noticed any recent change in my interest in sex. 
  1  I am less interested in sex than I used to be. 
  2  I have almost no interest in sex. 
  3  I have lost interest in sex completely. 
 
 
INTERPRETING THE BECK DEPRESSION INVENTORY (For researcher use only) 
 
Now that you have completed the questionnaire, add up the score for each of the twenty-one 
questions by counting the number to the right of each question you marked. The highest possible  
total for the whole test would be sixty-three. This would mean you circled number three on all  
twenty-one questions. Since the lowest possible score for each question is zero, the lowest 
possible  
score for the test would be zero. This would mean you circles zero on each question. 
 
You can evaluate your depression according to the Table below. 
 
Total Score ____________________  Levels of Depression 
1-10 ____________________  These ups and downs are considered normal 
11-16 ____________________  Mild mood disturbance 
17-20 ____________________  Borderline clinical depression 
21-30 ____________________  Moderate depression 
31-40 ____________________  Severe depression 
















Beck Anxiety Inventory 
Below is a list of common symptoms of anxiety. Please carefully read each item in the list. 
Indicate how much you have been bothered by that symptom during the past month, including 
today, by circling the number in the corresponding space in the column next to each symptom. 
 
 
 Not at 
All 
Mildly – but it 
didn’t bother 
me much. 
Moderately - it  
wasn’t pleasant  
at times 
Severely – it 
bothered me a 
lot 
Numbness or tingling 0 1 2 3 
Feeling hot 0 1 2 3 
Wobbliness in legs 0 1 2 3 
Unable to relax 0 1 2 3 
Fear of worst 
happening 0 1 2 3 
Dizzy or lightheaded 0 1 2 3 
Heart pounding/racing 0 1 2 3 
Unsteady 0 1 2 3 
Terrified or afraid 0 1 2 3 
Nervous 0 1 2 3 
Feeling of choking 0 1 2 3 
Hands trembling 0 1 2 3 
Shaky/unsteady 0 1 2 3 
Fear of losing control 0 1 2 3 
Difficulty in breathing 0 1 2 3 
Fear of dying 0 1 2 3 
Scared 0 1 2 3 
Indigestion 0 1 2 3 
Faint/lightheaded 0 1 2 3 
Face flushed 0 1 2 3 






For researcher use only 
 
 
Column Sum     
 
Scoring - Sum each column. Then sum the column totals to achieve a total score. Write that score 
below. 
 
Total Sum ______________________ 
Interpretation 
 
A grand sum between 0 – 21 indicates very low anxiety. That is usually a good thing. However, it 
is possible that you might be unrealistic in either your assessment which would be denial or that 
you have learned to “mask” the symptoms commonly associated with anxiety. Too little 
“anxiety” could indicate that you are detached from yourself, others, or your environment. 
 
A grand sum between 22 – 35 indicates moderate anxiety. Your body is trying to tell you 
something. Look for patterns as to when and why you experience the symptoms described above. 
For example, if it occurs prior to public speaking and your job requires a lot of presentations you 
may want to find ways to calm yourself before speaking or let others do some of the 
presentations. You may have some conflict issues that need to be resolved. Clearly, it is not 
“panic” time, but you want to find ways to manage the stress you feel. 
 
A grand sum that exceeds 36 is a potential cause for concern. Again, look for patterns or times 
when you tend to feel the symptoms you have circled. Persistent and high anxiety is not a sign of 
personal weakness or failure. It is, however, something that needs to be proactively treated or 
there could be significant impacts to you mentally and physically. You may want to consult a 

















Adapted from: Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical 





INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people do as part of 
their everyday lives. The questions will ask you about the time you spent being physically active 
in the last 7 days. Please answer each question even if you do not consider yourself to be an 
active person. Please think about the activities you do at work, as part of your house and yard 
work, to get from place to place, and in your spare time for recreation, exercise or sport. 
 
Think about all the vigorous and moderate activities that you did in the last 7 days. Vigorous 
physical activities refer to activities that take hard physical effort and make you breathe much 
harder than normal. Moderate activities refer to activities that take moderate physical effort and 
make you breathe somewhat harder than normal. 
 
PART 1: JOB-RELATED PHYSICAL ACTIVITY 
 
The first section is about your work. This includes paid jobs, farming, volunteer work, course 
work, and any other unpaid work that you did outside your home. Do not include unpaid work 
you might do around your home, like housework, yard work, general maintenance, and caring for 
your family. These are asked in Part 3. 
 
1. Do you currently have a job or do any unpaid work outside your home? 
 
  Yes 
 
 No Skip to PART 2: TRANSPORTATION 
 
The next questions are about all the physical activity you did in the last 7 days as part of your 
paid or unpaid work. This does not include traveling to and from work. 
 
2.  During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, digging, heavy construction, or climbing up stairs as part of your work? 
Think about only those physical activities that you did for at least 10 minutes at a time. 
 
_____ days per week 
 
 No vigorous job-related physical activity Skip to question 4 
 
3. How much time did you usually spend on one of those days doing vigorous physical 
activities as part of your work? 
 
_____ hours per day 




4. Again, think about only those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do moderate physical activities 
like carrying light loads as part of your work? Please do not include walking. 
 
_____ days per week 
 
No moderate job-related physical activity   Skip to 
question 6 
 
5.  How much time did you usually spend on one of those days doing moderate physical
 activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
6. During the last 7 days, on how many days did you walk for at least 10 minutes at a time 
as part of your work? Please do not count any walking you did to travel to or from 
work. 
 
_____ days per week 
 
 No job-related walking Skip to PART 2: TRANSPORTATION 
 
7. How much time did you usually spend on one of those days walking as part of your 
work? 
 
_____ hours per day 
_____ minutes per day 
 
PART 2: TRANSPORTATION PHYSICAL ACTIVITY 
 
These questions are about how you traveled from place to place, including to places like work, 
stores, movies, and so on. 
 
8. During the last 7 days, on how many days did you travel in a motor vehicle like a train, 
bus, car, or tram? 
 
_____ days per week 
 
 No traveling in a motor vehicle Skip to question 10 
 
9. How much time did you usually spend on one of those days traveling in a train, bus, car, 
tram, or other kind of motor vehicle? 
 
_____ hours per day 




Now think only about the bicycling and walking you might have done to travel to and from 
work, to do errands, or to go from place to place. 
 
10. During the last 7 days, on how many days did you bicycle for at least 10 minutes at a 
time to go from place to place? 
 
_____ days per week 
 
 No bicycling from place to place Skip to question 12 
 
11. How much time did you usually spend on one of those days to bicycle from place to 
place? 
 
_____ hours per day 
_____ minutes per day 
 
12. During the last 7 days, on how many days did you walk for at least 10 minutes at a time 
to go from place to place? 
 
_____ days per week 
 
 No walking from place to place Skip to PART 3: 
HOUSEWORK, HOUSE 
MAINTENANCE, AND 
CARING FOR FAMILY 
 
13. How much time did you usually spend on one of those days walking from place to place? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY 
 
This section is about some of the physical activities you might have done in the last 7 days in and 
around your home, like housework, gardening, yard work, general maintenance work, and caring 
for your family. 
 
14. Think about only those physical activities that you did for at least 10 minutes at a time. 
During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, chopping wood, shoveling snow, or digging in the garden or yard? 
 
_____ days per week 
 





15. How much time did you usually spend on one of those days doing vigorous physical 
activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
16. Again, think about only those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do moderate activities like 
carrying light loads, sweeping, washing windows, and raking in the garden or yard? 
 
_____ days per week 
 
 No moderate activity in garden or yard Skip to question 18 
 
17. How much time did you usually spend on one of those days doing moderate physical 
activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
18. Once again, think about only those physical activities that you did for at least 10 minutes 
at a time. During the last 7 days, on how many days did you do moderate activities like 
carrying light loads, washing windows, scrubbing floors and sweeping inside your 
home? 
 
_____ days per week 
 





19. How much time did you usually spend on one of those days doing moderate physical 
activities inside your home? 
 
_____ hours per day 
_____ minutes per day 
 
PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL ACTIVITY 
 
This section is about all the physical activities that you did in the last 7 days solely for recreation, 
sport, exercise or leisure. Please do not include any activities you have already mentioned. 
 
20. Not counting any walking you have already mentioned, during the last 7 days, on how 
many days did you walk for at least 10 minutes at a time in your leisure time? 
 
_____ days per week 
 





21. How much time did you usually spend on one of those days walking in your leisure 
time? 
 
_____ hours per day  _____ minutes per day 
 
22. Think about only those physical activities that you did for at least 10 minutes at a time. 
During the last 7 days, on how many days did you do vigorous physical activities like 
aerobics, running, fast bicycling, or fast swimming in your leisure time? 
 
_____ days per week 
 
 No vigorous activity in leisure time Skip to question 24 
 
23. How much time did you usually spend on one of those days doing vigorous physical 
activities in your leisure time? 
 
_____ hours per day  _____ minutes per day 
 
24. Again, think about only those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do moderate physical activities 
like bicycling at a regular pace, swimming at a regular pace, and doubles tennis in your 
leisure time? 
 
_____ days per week 
 
 No moderate activity in leisure time  Skip to PART 5: TIME 
SPENT SITTING 
 
25. How much time did you usually spend on one of those days doing moderate physical 
activities in your leisure time? 
_____ hours per day  _____ minutes per day 
 
PART 5: TIME SPENT SITTING 
The last questions are about the time you spend sitting while at work, at home, while doing 
course work and during leisure time. This may include time spent sitting at a desk, visiting 
friends, reading or sitting or lying down to watch television. Do not include any time spent sitting 
in a motor vehicle that you have already told me about. 
 
26. During the last 7 days, how much time did you usually spend sitting on a weekday? 
 
_____ hours per day  _____ minutes per day 
 
27. During the last 7 days, how much time did you usually spend sitting on a weekend day? 
 






Adapted from: Booth M. Assessment of physical activity: An International perspective. Research 





Ketogenic Diet Handout 
Participant ID #: ________________ 
 
Welcome to our research study and thank you for your participation!  If you have any questions 
or concerns at any time during your participation, please contact our research team. 
 
Graduate Student Researcher    Research Supervisor 
Jordan Murrin       Jeremy Akers, PhD, RDN 
murrinja@dukes.jmu.edu     akersjd@jmu.edu 
703-565-3001       540-568-8974 
 
Appendix A – Ketogenic Diet 
 
The ketogenic diet is a dietary plan that is high in fat and very low in carbohydrates, while 
maintaining adequate protein intake.  It requires a restriction of carbohydrate intake to achieve 
“ketosis”, which mimics a fasted state and forces the body to utilize fats from your diet and those 
stored in your body for fuel.  As these fats are broken down for energy, they are turned into 
ketones, which replace most of your body’s carbohydrates as a major source for energy. 
 
To benefit from the ketogenic diet, it is important to eat foods that are low in carbohydrates and 
to eat the appropriate number of calories to achieve and maintain a healthy weight.  The diet 
typically includes plenty of fatty fish, meats, eggs, nuts, seeds, vegetable-based oils, and fibrous 
vegetables. 
 
This handout is meant to provide you with recommendations that you may use to maintain the 
ketogenic diet. The main goal for the ketogenic diet is to achieve ketosis by restricting your total 
carbohydrate intake to less than 50 grams of carbohydrates per day. You can accomplish this 
by reading nutrition labels on food, planning your meals, and even using the provided resources 
to make “keto-friendly” recipes. 
 
The tables on the next page outlines the main food groups and provides instructions for making 
food choices that are higher in fat and lower in carbohydrate. An emphasis on foods high 
in saturated fat is not recommended by the Dietary Guidelines for Americans and the American 
Heart Association and may have adverse effects on blood LDL cholesterol. Therefore, for this 
diet, you should emphasize high-total fat foods that are also lower in saturated fat such as fatty 
fish, avocado, nuts, seeds, and vegetable-based oils (includes canola, corn, olive, peanut, 
















for Active Activity 
Level 
19–30 2,400 – 2,600 2,600–2,800 3,000 
31–50 2,200-2,400 2,400–2,600 2,800–3,000 
51+ 2,000-2,200 2,200–2,400 2,400–2,800 
 










for Active Activity 
Level 
19–30 1,800-2,000 2,000-2,200 2,400 
31–50 1,800 2,000 2,200 
51+ 1,600 1,800 2,200 
 
 
Tips for Eating Out on Keto 
 
• Avoid starches 
o Ask for your food to be served without bread, pasta, potatoes, or rice 
o Be wary of starchy vegetables like potatoes (all types/forms), corn, peas, 
beets, carrots, or onions 
o See the “Low Carbohydrate Foods and Foods to Avoid” handout to 
determine what foods should be avoided 
• Add healthy fat 
o Ask for extra butter for veggies or meat 
o Use olive oil and vinegar dressing 
o Use heavy cream or coconut milk in your coffee or tea 
• Watch out for sauces and condiments 
o Some contain mostly fat, but others have added sugars 
• Choose the appropriate drink 
o Plain water, sparkling water (no sugar added), tea, or coffee are great 
options 
o Avoid sugar-sweetened beverages, juices, and alcohol 
• Rethink dessert 
o Most dessert are not only high in fat, but added sugars too 






Appendix B - Low Carbohydrate Foods and Foods to Avoid 
 
This handout is meant to give you a better idea of what foods to choose in order to maintain your 
low-carbohydrate diet. It will give you general DOs and DON’Ts in terms of food choices so that 
you have a general idea of some low-carb and high-carb foods. The first column will consist of 
your low-carb foods, while the “avoid” column will consist of high-carb foods that you will want 
to avoid and eliminate from your diet. Keep in mind that this list is not exhaustive and there other 
low-carb foods that are not on this list. 
Experimenting and combining low-carb foods in different ways will keep your diet from 
becoming monotonous. Meal prepping in advance may be beneficial if you have limited time 
during the week to cook meals so that you always have food ready to eat. Having meals and 
snacks ready in advance may also prevent any temptation or impulse to eat high-carb foods that 
are not permitted while following this regiment. 
It is important to pay attention to what you eat because some of these foods do contain 
carbohydrates. If you over-consume a particular food, you may easily go over your daily 50 g 
CHO limit. Yogurt and cottage cheese especially should be consumed in moderation. 
 
 
Zero/Low CHO foods Avoid 

























(all un-breaded meat) 
Any breaded meats or fish 







Cottage cheese (1/2 c) 
Brie (1 oz) 
Camembert (1 oz) 
Blue cheese (1 oz) 
Cheddar (1 oz) 
Sheep and goat cheeses 
(1 oz) 
Mozzarella (1 oz) 
Whole milk (<1c/day) 
High-fat yogurts (plain 
only) 






Feta (1 oz) 
Ice cream 
Yogurts with added fruit 
Low fat dairy 
Milk 
Oils, Fats, & 
Nuts/Seeds 
Peanut butter (no added 
sugar) 



























































Fruits No fruit allowed Avoid all fruit 
Grains No grains allowed Avoid all breads, pastas, 



























Balsamic vinegar  
Caesar (2 tbs) 
Italian (2 tbs) 
Oil and vinegar (2 tbs) 
Blue cheese (2 tbs) 
Ranch (2 tbs) 
No dressings with added 
sugar and no more than 2 
grams of net carbs per 
serving 




















Jams, jellies, preserves 
Chips, pretzels 
Cookies, cakes, candy 
Ketchup, Tartar sauce 
Steak sauce 
Barbeque sauce 
*Check all labels for added sugars or fillers that may add carbs 
 
**Alcoholic beverages should be minimized, as alcohol reduces 
ketosis** 
However, there are some low carbohydrate beers available, such as 




*DO NOT UTILIZE ANY EXOGENOUS KETO 
SUPPLEMENTS* 





Appendix C - Sample Menus 
 
Sample Menu 1 
 
Breakfast (534 kcal, 6g carbs) 
Omelet 
 3 eggs        214 kcal, 1g carbs 
 1.5 tbsp of butter      152 kcal 
 ¼ cup cheddar cheese      114 kcal 
 ½ avocado       109 kcal, 5g carbs 
 
Snack (149 kcal, 12g carbs) 
8 ounces of whole milk      149kcal, 12g carbs 
 
Lunch (657 kcal, 1g carbs) 
6 oz 80% lean hamburger patty, no bun    470kcal 
1 slice of provolone cheese      100kcal, 1g carbs 
2 medium slices of bacon      87kcal 
 
Snack (204 kcal, 11g carbs) 
1 cup of celery        16 kcal, 3g carbs 
2 tbsp. of peanut butter      188kcal, 8g carbs 
 
Dinner (662 kcal, 6g carbs) 
6-ounce chicken leg quarter, skin eaten    392kcal 
1 cup of broccoli       30kcal, 6g carbs 
2 tbsp. of canola oil       240kcal 
 






Sample Menu 2 
 
Breakfast (379 kcal, 12g carbs) 
2 medium slices of bacon      87 kcal 
2 large hard-boiled eggs      154kcal, 1g carbs 
8 ounces full fat plain yogurt      138kcal, 11g carbs 
 
Snack (171 kcal, 2g carbs) 
2 ounces of mozzarella cheese (2 slices or 2 cheese sticks)  171kcal, 2g carbs 
 
Lunch (611 kcal, 7g carbs) 
6-ounce pork chop       405kcal 
1 cup of cottage cheese      206kcal, 7g carbs 
 
Snack (321 kcal, 17g carbs) 
8 ounces of whole milk      149kcal, 12g carbs 
1 ounce of almonds (22 almonds)     172kcal, 5g carbs 
 
Dinner (756 kcal, 4g carbs) 
6-ounce steak, fat eaten      404kcal 
2 cups of raw spinach       14kcal, 2g carbs 
¼ cup of feta cheese       99 kcal, 2g carbs 
2 tbsp. of olive oil       239kcal 
 
 






















1) Baked Eggs with Coconut Milk and Cilantro 
a) Ingredients 
i) Virgin coconut or vegetable oil (for ramekins) 
ii) 2 large eggs 
iii) 2 tablespoons unsweetened coconut milk 
iv) Kosher salt 
v) ½ cup cilantro leaves with tender stems 
vi) 1 teaspoon fresh lime juice 
vii) 1 teaspoon green hot sauce 
viii) Store-bought fried shallots (for serving) 
b) Instructions 
i) Preheat oven to 300°. Coat 2 small ramekins or other ovenproof dishes with 
oil. Add 1 large egg and 1 Tbsp. coconut milk to each. Set on a rimmed 
baking sheet and bake until eggs are barely set, 11–14 minutes; season with 
salt. 
ii) Toss cilantro in a small bowl with lime juice and hot sauce; season with salt. 
Top eggs with cilantro mixture and shallots. 
2) Keto Pancakes 
a) Ingredients 
i) 2 cups almond flour 
ii) 8 tbsp butter, melted 
iii) 1 tbsp avocado oil (or coconut) 
iv) 1/4 cup water 
v) 4 eggs 




vii) 1 tsp baking powder 
viii) 2 tbsp sweetener of choice 
ix) pinch of salt 
x) extra butter for griddle 
b) Instructions 
i) Combine all ingredients in blender or food processor. Let mix until fully 
combined. Let batter rest 5 minutes before cooking. 
ii) Set a griddle (or nonstick skillet) to MED LOW heat. Use a 1/3 cup measuring 
cup to portion out pancake batter. 
iii) Cook until edges are firming up. The pancakes will not bubble up like 
traditional ones but there will be little bubbles. 
iv) Flip and cook 1 additional minute. 
v) Serve hot with a pat of butter and sugar free maple syrup 
3) Frittata with spinach 
a) Ingredients 
i) 5 oz. diced bacon or chorizo 
ii) 2 tbsp butter 
iii) 8 oz. fresh spinach 
iv) 8 eggs 
v) 1 cup heavy whipping cream 
vi) 5 oz. shredded cheese 
vii) salt and pepper 
b) Instructions 
i) Preheat the oven to 350°F (175°C). Grease a 9x9 baking dish or individual 
ramekins. 
ii) Fry the bacon in butter on medium heat until crispy. Add the spinach and stir 
until wilted. Remove the pan from the heat and set aside. 
iii) Whisk the eggs and cream together and pour into baking dish or in ramekins. 
iv) Add the bacon, spinach and cheese on top and place in the middle of the oven. 
Bake for 25–30 minutes or until set in the middle and golden brown on top. 
 
Lunch/Dinner 
1) Keto Chicken Enchilada Bowl 
a) Ingredients 
i) 2 tablespoons coconut oil (for searing chicken) 
ii) 1 pound of boneless, skinless chicken thighs 
iii) 3/4 cup red enchilada sauce 
iv) 1/4 cup water 
v) 1/4 cup chopped onion 
vi) 1– 4 oz can diced green chilis 




(1) 1 whole avocado, diced 
(2) 1 cup shredded cheese (I used mild cheddar) 
(3) 1/4 cup chopped pickled jalapenos 
(4) 1/2 cup sour cream 
(5) 1 roma tomato, chopped 
viii) Optional: serve over plain cauliflower rice for a more complete meal! 
b) Instructions 
i) In a pot or dutch oven over medium heat melt the coconut oil. Once hot, sear 
chicken thighs until lightly brown. 
ii) Pour in enchilada sauce and water then add onion and green chilis. Reduce 
heat to a simmer and cover. Cook chicken for 17-25 minutes or until chicken 
is tender and fully cooked through to at least 165 degrees internal temperature. 
iii) Carefully remove the chicken and place onto a work surface. Chop or shred 
chicken (your preference) then add it back into the pot. Let the chicken 
simmer uncovered for an additional 10 minutes to absorb flavor and allow the 
sauce to reduce a little. 
iv) To Serve, top with avocado, cheese, jalapeno, sour cream, tomato, and any 
other desired toppings. Feel free to customize these to your preference. Serve 
alone or over cauliflower rice if desired just be sure to update your personal 
nutrition info as needed. 
2) Lemon Butter Fish 
a) Ingredients 
i) LEMON BUTTER SAUCE: 
(1) 60 g / 4 tbsp unsalted butter, cut into pieces 
(2) 1 tbsp fresh lemon juice 
(3) Salt and finely ground pepper 
ii) CRISPY PAN-FRIED FISH: 
(1) 2 x thin white fish fillets (120-150g / 4-5oz each), skinless boneless (I 
used Bream, Note 1) 
(2) Salt and pepper 
(3) 2 tbsp white flour 
(4) 2 tbsp oil  
iii) SERVING: 
(1) Lemon wedges 
(2) Finely chopped parsley, optional 
b) Instructions 
i) LEMON BUTTER SAUCE: 





(2) Melt butter then leave on the stove, whisking / stirring every now and 
then. When the butter turns golden brown and it smells nutty - about 3 
minutes, remove from stove immediately and pour into small bowl. (Note 
2) 
(3) Add lemon juice and a pinch of salt and pepper. Stir then taste when it has 
cooled slightly. Adjust lemon/salt to taste. 
(4) Set aside - it will stay pourable for 20 - 30 minutes. See Note 3 for storing. 
ii) CRISPY PAN-FRIED FISH: 
(1) Pat fish dry using paper towels. Sprinkle with salt & pepper, then flour. 
Use fingers to spread flour. Turn and repeat. Shake excess flour off well, 
slapping between hands if necessary. 
(2) Heat oil in a non-stick skillet over high heat. When the oil is shimmering 
and there are faint wisps of smoke, add fish. Cook for 1 1/2 minutes until 
golden and crispy on the edges, then turn and cook the other side for 1 1/2 
minutes (cook longer if you have thicker fillets). 
(3) Remove immediately onto serving plates. Drizzle each with about 1 tbsp 
of Sauce (avoid dark specks settled at the bottom of the bowl), garnish 
with parsley and serve with lemon on the side.  
3) Caveman Chili 
a) Ingredients 
i) 2 pounds ground pork 
ii) 8 thick slices bacon, chopped 
iii) 1 (14.5 ounce) can diced tomatoes, drained 
iv) 1 onion, chopped 
v) 3 small green bell peppers, chopped 
vi) 1 (6 ounce) can tomato paste 
vii) 1 (1.25 ounce) package chili seasoning (such as McCormick®) 
viii) 1 pinch garlic powder, or more to taste 
ix) 1 pinch onion powder, or more to taste 
x) salt and ground black pepper to taste 
xi) 1 pinch ground cayenne pepper, or more to taste 
b) Instructions 
i) Place pork in a skillet over medium heat; season with salt and pepper. Cook 
and stir until browned and crumbly, 5 to 7 minutes. Drain and discard grease. 
Transfer pork to a slow cooker. 
ii) Place bacon in the hot skillet and cook over medium-high heat until evenly 





iii) Combine drained tomatoes, onion, green bell pepper, and tomato paste into 
the slow cooker. Add seasoning packet, garlic powder, onion powder, and salt, 
pepper, cayenne pepper; stir to combine. 
iv) Cook on Low until flavors have combined, about 6 hours. 
 
Snacks 
1) Bacon Blue Cheese Deviled Eggs 
a) Ingredients 
i) 8 hard-boiled eggs 
ii) ¼ cup sour cream 
iii) 1/3 cup mayonnaise 
iv) 1 Tablespoon Dijon mustard 
v) ½ teaspoon kosher salt 
vi) ¼ teaspoon pepper 
vii) ¼ teaspoon dill 
viii) ¼ cup crumbled blue cheese 
ix) 3 slices of cooked bacon chopped fine 
x) Parsley for garnish 
b) Instructions 
i) To boil the perfect egg, simply place raw eggs in cold water and bring to a 
boil. Once your reach a boil, set a timer for 10 minutes. When time is up, 
drain and rinse the eggs in cold water and peel as soon as they are cool enough 
to handle. 
ii) Cut each hard-boiled egg in half and place the cooked yolk into a bowl and 
the cooked egg white onto an egg plate. 
iii) With a fork, mash the egg yolks until they resemble coarse crumbs. Add in the 
sour cream, mayo, mustard and salt and pepper and mix very well until the 
mixture is creamy (you could do this in a food processor if you wanted). Stir 
in the remaining ingredients and taste the filling for seasoning. If the filling 
seems a little dry, add in a spoonful more mayo 
2) Keto Fat Bombs 
a) Ingredients 
i) 2 tablespoons coconut oil 
ii) 2 tablespoons cocoa powder unsweetened 
iii) 1/2 cup natural peanut butter 
iv) 1/4 cup chia seeds 
v) 1 teaspoon vanilla essence 
vi) 2 tablespoons xylitol (or your preferred sweetener) 





i) Melt Coconut Oil 
ii) Put all ingredients "except melted coconut oil and shredded coconut" into a 
bowl and mix well. 
iii) Add melted coconut oil and mix until combined. Place the mixture in the 
fridge for 30 minutes to allow the chia seeds to soak up the excess liquid and 
the coconut oil to set. 
iv) Spread shredded coconut out onto a flat dinner plate or tray. 
v) Take one heaped tablespoon of the mix and roll it into a ball in the palm of 
your hand. 
vi) Roll the fat bomb around in the shredded coconut until coated and place on a 
tray lined with baking paper. 
vii) When all of the mix has been rolled into fat bombs, place the tray in the 
refrigerator for 1 hour, or until the balls have firmed up. 
viii) When the fat bombs are firm, they're ready to eat. Keep them in the fridge 
(particularly if you live in hot climates), they will keep for a week. 
3) Buffalo Chicken Sausage Balls 
a) Ingredients 
i) Sausage Balls: 
(1) 2 14- ounce packages al fresco fresh Buffalo-Style chicken 
sausage casings removed 
(2) 2 cups almond flour 
(3) 1 ½ cups shredded cheddar cheese 
(4) ½ cup crumbled blue cheese optional 
(5) 1 tsp salt 
(6) ½ tsp pepper 
ii) Blue Cheese Ranch Dipping Sauce: 
(1) 1/3 cup mayonnaise 
(2) 1/3 cup unsweetened almond milk can substitute regular milk 
(3) 2 cloves garlic minced 
(4) 1 tsp dried dill 
(5) ½ tsp dried parsley 
(6) ½ tsp salt 
(7) ½ tsp pepper 
(8) ¼ cup crumbled blue cheese or more, if desired 
b) Instructions 
i) Sausage Balls: 
(1) Preheat oven to 350F and line two large baking sheets with parchment 
paper or tin foil. 
(2) In a large bowl, combine sausage, almond flour, cheddar cheese, bleu 




(3) Roll into 1-inch balls and place about an inch apart on prepared baking 
sheets. Bake 25 minutes, until golden brown. Serve warm with dipping 
sauce. 
ii) Dipping Sauce: 
(1) While sausage balls are baking, combine mayonnaise, almond milk, garlic, 
dill, parsley, salt, and pepper in a medium bowl. Stir well and then mix in 





Appendix E - Dietary Compliance Checklist 
You have been randomized to the Ketogenic diet group.  For more details on your assigned diet, 
please see handout titled “Low Carbohydrate Foods and Foods to Avoid”.  This checklist can be 
used to ensure compliance with your ketogenic diet, by tracking intake of these items for your 
reference when completing your online weekly check-in survey. During the weekly check-in, you 
will be asked to indicate if you consumed any of the foods listed here, and provide the food item 




(circle all that apply) 
Item Quantity 
Monday 





Breads (bagels, toast, 
buns, English muffins) 
Cereal (hot or cold) 
Candy, Cookies, Cakes, 
Chips 










Breads (bagels, toast, 
buns, English muffins) 
Cereal (hot or cold) 
Candy, Cookies, Cakes, 
Chips 
















Breads (bagels, toast, 
buns, English muffins) 
Cereal (hot or cold) 
Candy, Cookies, Cakes, 
Chips 











Breads (bagels, toast, 
buns, English muffins) 
Cereal (hot or cold) 
Candy, Cookies, Cakes, 
Chips 














Breads (bagels, toast, 
buns, English muffins) 
Cereal (hot or cold) 
Candy, Cookies, Cakes, 
Chips 











Breads (bagels, toast, 
buns, English muffins) 
Cereal (hot or cold) 
Candy, Cookies, Cakes, 
Chips 














Breads (bagels, toast, 
buns, English muffins) 
Cereal (hot or cold) 
Candy, Cookies, Cakes, 
Chips 










Appendix F – Urinary Ketone Daily Record 
 
You have been randomized to the Ketogenic diet group.   This record is designed to assess your 
compliance with your assigned diet by measuring ketones in your urine.  You will test your 
urine each morning before having anything to eat or drink (except plain water). Drinking 
plain water is encouraged to ensure that you are hydrated and can produce the required urinary 
sample. You will report these results to your researcher each week along with your Dietary 
Compliance Checklist during your online weekly check-in survey. 
 
To test your urinary ketones, follow these steps: 
1) Collect a small sample of your urine in one of the provided cups. 
2) Place the end of the ketone testing strip in the urine sample and let it to sit for the 
specified time listed in the instructions on the testing strips bottle. 
3) After this time has passed, remove the testing strip from the urine sample and 
compare the color of the testing strip to the provided chart on the testing strips 
bottle. 
4) Use the matching color to determine whether your sample was a positive or 
negative for ketones. 
5) Indicate your daily result in the chart – write “+” for a positive test result and “−” 
for a negative test result. 
 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Week 0        
Week 1        
Week 2        
Week 3        
Week 4        
Week 5        
Week 6        
Week 7        
Week 8        
Week 9        
Week 10        
Week 11        
Week 12        




Food Intake Record  
Day  1 2 3 4  Date: ______________ 





Time Meal Location 
(restaurant, home, 
work, etc.) 
Name of Food Item or 
Beverage (provide as 
much detail as possible, 
one food item per line) 
Amount consumed (cups, tsp., Tbsp., 
ounces, etc.) 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     




DASH Diet Handout 
 
Participant ID #: ________________ 
 
Welcome to our research study and thank you for your participation!  If you have any questions 
or concerns at any time during your participation, please contact our research team. 
 
Graduate Student Researcher    Research Supervisor 
Jordan Murrin       Jeremy Akers, PhD, RDN 
murrinja@dukes.jmu.edu     akersjd@jmu.edu  
703-565-3001       540-568-8974 
 
Appendix A – DASH Diet 
 
Dietary Approaches to Stop Hypertension (DASH) is a balanced eating plan that promotes life-
long heart-healthy dietary patterns.  It does not require any specific foods, but instead 
recommends: 1) eating a wide variety of vegetables, fruits, and whole grains; 2) moderating 
consumption of fat-free or low-fat dairy products, fish, poultry, beans, nuts, and vegetable oils; 
and 3) limiting foods that are high in saturated fat, such as fatty meats, full-fat dairy products, and 
tropical oils such as coconut, palm kernel, and palm oils.  
 
To benefit from DASH, it is important to eat the appropriate number of calories to achieve and 
maintain a healthy weight.  You can accomplish this by reading nutrition labels on food, planning 
your meals, and even using the provided resources to make heart-healthy recipes. 
 
This handout is meant to provide you with recommendations that you may use to maintain the 
DASH diet.  The tables on the next page outlines the main food groups and provides the 
approximate number of daily servings, different amounts of foods that equal one serving size, and 
examples of nutritious foods for each group. By following these recommendations, your diet will 
be: lower in saturated and trans fats; higher in potassium, calcium, magnesium, fiber, and protein; 
and lower in sodium.  Additional tips for lowering your intake of sodium/salt are provided below. 
 










for Active Activity 
Level 
19–30 2,400 2,600–2,800 3,000 
31–50 2,200 2,400–2,600 2,800–3,000 
51+ 2,000 2,200–2,400 2,400–2,800 
 













for Active Activity 
Level 
19–30 1,800-2,000 2,000-2,200 2,400 
31–50 1,800 2,000 2,200 
51+ 1,600 1,800 2,200 
 
Ways to Control Calories 
 
The DASH eating plan can be used to help you lose weight. To lose weight, follow the DASH 
eating plan and try to reduce your total daily calories gradually. Find out your daily calorie needs 
or goals using a Body Weight Planner and calorie chart. 
 
General tips for reducing daily calories include: 
• Eat smaller portions more frequently throughout the day. 
• Reduce the amount of meat that you eat while increasing the amount of fruits, vegetables, 
whole grains, or dry beans. 
• Substitute low-calorie foods, such as when snacking (choose fruits or vegetables instead 
of sweets and desserts) or drinking (choose water instead of soda or juice), when 
possible. 
 
Increasing Daily Potassium 
 
The DASH eating plan is designed to be rich in potassium, with a target of 4,700 mg potassium 
daily, to enhance the effects of reducing sodium on blood pressure. The following are examples 
of potassium-rich foods. 
 
Food Potassium (mg) Food Potassium (mg) 
Potato, 1 small 738 Prunes, stewed, ½ cup 398 
Plain yogurt, nonfat or 
low-fat, 8 ounces 530–570 Skim milk, 1 cup 382 
Sweet potato, 1 
medium 542 Apricots, ¼ cup 378 
Orange juice, fresh, 1 
cup 496 
Pinto beans, cooked, ½ 
cup 373 
Lima beans, ½ cup 478 Pork tenderloin, 3 ounces 371 
Soybeans, cooked, ½ 
cup 443 Lentils, cooked, ½ cup 365 
Banana, 1 medium 422 Kidney beans, cooked, ½ cup 360 
Fish (cod, halibut, 
rockfish, trout, tuna), 
3 ounces 
200–400 Split peas, cooked, ½ cup 360 





Tips for Lowering Sodium When Shopping, Cooking, and Eating Out 
 
• Shopping 
o Choose items that are lower in sodium and salt, particularly frozen or 
prepackaged convenience foods and condiments. 
o Choose fresh lean meats, poultry, and fish instead of cured food such as bacon 
and ham. 
o Choose fresh or frozen versus canned fruits and vegetables. 
o Avoid food with added salt, such as pickles, pickled vegetables, olives, and 
sauerkraut. 
o Avoid instant or flavored rice and pasta. 
• Cooking 
o Don’t add salt when cooking rice, pasta, and hot cereals. 
o Flavor your foods with salt-free seasoning blends, fresh or dried herbs and spices, 
or fresh lemon or lime juice. 
o Rinse canned foods or foods soaked in brine to remove the sodium. 
o Use less table salt to flavor food. 
• Eating Out 
o Ask that foods be prepared without added salt. 
o Avoid choosing menu items that have salty ingredients such as bacon, pickles, 
olives, and cheese or that include foods that are pickled, cured, smoked, or made 
with soy sauce or broth. 





DASH Daily Eating Plan for 2000 Calories 
Food Groups Servings 
per day 




6 – 8  
1 slice bread 
1 cup ready-to-eat cerealb 
½ cup cooked rice, pasta, or cerealb 
Whole-wheat bread and rolls, whole-wheat pasta, 
English muffin, pita bread, bagel, cereals, grits, 
oatmeal, brown rice, unsalted pretzels and popcorn 
Lean meats, poultry, 
and fish 
 
6 or less 
 
1-ounce cooked lean meat, skinless poultry, or 
fish 
1 egg 
Select only lean; trim away visible fats; broil, roast, or 




4 – 5  
1 cup raw leafy vegetable 
½ cup cooked vegetable 
6 ounces vegetable juice 
Broccoli, carrots, collards, green beans, green peas, 





4 – 5  
1 medium fruit 
¼ cup dried fruit 
½ cup fresh, frozen, or canned fruit 
6 ounces 100% fruit juice 
Apples, apricots, bananas, dates, grapes, oranges, 
grapefruit, grapefruit juice, mangoes, melons, peaches, 
pineapples, raisins, strawberries, tangerines 
Low-fat or fat-free 
dairy productsc 
 
2 – 3  
8 ounces 1% or skim milk 
1 cup low-fat or nonfat yogurt 
1½ ounces part-skim cheese 
Fat-free milk or buttermilk; fat-free, low-fat, or 
reduced-fat cheese; fat-free/low-fat regular or frozen 
yogurt 
 
Fats and oilsd 
 
2 – 3  
1 teaspoon soft margarine 
1 tablespoon low-fat mayonnaise 
2 tablespoons light salad dressing 
1 teaspoon vegetable oil 
Soft margarine, vegetable oil (canola, corn, olive, 
safflower), low-fat mayonnaise, light salad dressing 
 
Nuts, seeds, and 
legumes (dry beans) 
 
4 – 5  
per week 
1/3 cup or 1½ ounces nuts 
2 tablespoon nut butter 
2 tablespoon or ½ ounce seeds 
½ cup cooked dry beans 
Almonds, filberts, mixed nuts, peanuts, walnuts, 
sunflower seeds, peanut butter, kidney beans, lentils, 
split peas 
 
Sweets and added 
sugars 
 
5 per week 
1 tablespoon sugar 
1 tablespoon jelly or jam 
½ ounce jelly beans 
8 ounces lemonade 
Fruit-flavored gelatin, fruit punch, hard candy, jelly, 




£ 2,300 mg 
Low sodium: £ 140 mg* 
Very low: £ 35 mg* 
Sodium free: £ 5 mg* 
*mg of sodium per serving 
Water ~ 3.7 L  




a Whole grains are recommended for most grain servings as a good source of fiber and nutrients. 
b Serving sizes vary between ½ cup and 1¼ cups, depending on cereal type. Check the product's 
Nutrition Facts label. 
c For lactose intolerance, try either lactase enzyme pills with dairy products or lactose-free or 
lactose-reduced milk. 
d Fat content changes the serving amount for fats and oils. For example, 1 Tbsp regular salad 
dressing = one serving; 1 Tbsp low-fat dressing = one-half serving; 1 Tbsp fat-free dressing = 
zero servings. 
e The DASH eating plan has a sodium limit of either 2,300 mg or 1,500 mg per day.  1,500 mg of 







































Appendix B – Sample Menus 
 
Sample Menu 1 
 
Breakfast (376 kcal, 70 g carbs, 6 g fat, 16  g protein, 421 mg sodium, 33 g sugar) 
- ½ cup whole grain cereal with raisins, low-fat 
- 1 cup 1% milk 
- 1 slice 100% whole wheat toast 
- 1 tbsp jelly/jam 
Snack (285 kcal, 34 g carbs, 6 g fat, 26 g protein, 285 mg sodium, 9 g sugar) 
 - 1 cup plain nonfat Greek yogurt 
- ¼ cup grain cereal/oats (on top of yogurt) 
Lunch (558 kcal, 97 g carbs, 9 g fat, 26 g protein, 495 mg sodium, 22 g sugar) 
 - 3 oz Oven-roasted Chicken Breast 
- 1 cup Brown Rice 
- 1 cup Mixed Vegetables 
- 1 medium fruit 
Snack (427 kcal, 32 g carbs, 27 g fat, 13 g protein, 107 sodium, 24 g sugar) 
 - 1/2 cup trail mix (nuts, dried fruit, seeds, dark chocolate chips) 
Dinner (487 kcal, 67 g carbs, 11 g fat, 33 g protein, 904 sodium, 12 g sugar) 
 - 3 oz Flank Steak 
- 2/3 cup Rice Pilaf 
- ½ cup baked sweet potato fries 
- 1 cup steamed collard greens 
- ½ cup grapes 
 







Sample Menu 2 
 
Breakfast (518 kcal, 74 g carbs, 9 g fat, 41 g pro,  528 mg sodium, 25 g sugar) 
 - 1 eggs, scrambled 
- 1 slice 100% whole wheat toast 
- 1 cup plain nonfat Greek yogurt 
- ¼ cup grain cereal/oats (on top of yogurt) 
- 1 cup mixed berries 
Snack (188 kcal, 14 g carbs, 14 g fat, 7 g protein, 0 mg sodium, 7 g sugar) 
- 3 tbsp whole almonds  
- ½ cup fresh fruit 
Lunch (534 kcal, 88 g carbs,  5 g fat, 19 g protein, 548 mg sodium, 20 g sugar) 
 - 3 oz teriyaki (low sodium) salmon 
- 1 cup stir-fried vegetables 
- 1 cup Brown Rice 
- 1 medium fruit 
Snack (200 kcal, 20 g carbs, 10 g fat, 10 g protein, 370 mg sodium, 1 g sugar) 
- 1 oz nonfat or light butter popcorn 
- 1 part-skim cheese stick or 1 oz low fat cheese 
Dinner (514 kcal, 51 g carbs, 21 g fat, 26 g protein, 531 mg sodium, 20 g sugar) 
- 3 oz baked pork loin 
- 2 oz square cornbread  
- ½ cup natural low sodium applesauce 
- 1 cup steamed baby carrots 
 

















4. https://www.foodnetwork.com/healthyeats/recipes ‘ 
 






1) Cinnamon-glazed Baby Carrots 
a) 4 cups baby carrots, rinsed and split lengthwise if very thick (or frozen pre-sliced 
carrots); 2 tbsp soft tub margarine; 2 tbsp brown sugar; ½ tsp ground cinnamon; 1/8 tsp 
salt 
b) Directions 
i) Place the carrots in a small saucepan. Add just enough water to barely cover the 
carrots. Cover. Bring to a boil. Reduce heat to medium. Cook for 7–8 minutes, just 
until the carrots are easily pierced with a sharp knife.  
ii) While the carrots are cooking, combine margarine, brown sugar, cinnamon, and salt 
in a small saucepan, and melt together over low heat (or put in a microwave-safe 
bowl and microwave for a few seconds on high power, until margarine is mostly 
melted). Stir well to combine ingredients.  
iii) Drain carrots, leaving them in the saucepan. Pour cinnamon mixture over carrots. 
Cook and stir over medium heat for 2–3 minutes, just until the carrots are thoroughly 
coated and the glaze thickens slightly. Serve warm. 
2) Good-for-you Cornbread 
a) 1 cup cornmeal; 1 cup flour; ¼ cup sugar; 1 tsp baking powder; 1 cup low-fat (1%) 
buttermilk; 1 large egg; ¼ cup soft tub margarine; 1 tsp vegetable oil (to grease baking 
pan) 
b) Directions 
i) Preheat oven to 350 °F. 
ii) Mix together cornmeal, our, sugar, and baking powder.  
iii) In another bowl, combine buttermilk and egg. Beat lightly. Slowly add buttermilk 
and egg mixture to dry ingredients. Add margarine and mix for 1 minute.  






3) Greek Style Flank Steak with tangy yogurt sauce 
a) 1 beef flank steak (12 oz) 
b) For marinade: ¼ cup lemon juice; 1 tbsp olive oil; 2 tsp fresh oregano, rinsed dried and 
chopped (or ½ tsp dried); 1 tbsp garlic, minced (about 2-3 cloves) 
c) For yogurt sauce: 1 cup cucumber, peeled, seeded, and chopped; 1 cup nonfat plain 
yogurt; 2 tbsp lemon juice; 1 tbsp fresh dill rinsed dried and chopped (or ½ tsp dried); 1 
tbsp garlic, minced (about 2-3 cloves); ½ tsp salt 
d) Directions 
i) For the marinade, combine lemon juice, olive oil, oregano, and garlic in a large bowl. 
ii) Lay steak in a container with sides and pour marinade over the steak. Let the steak 
marinate for at least 20 minutes or up to 24 hours, turning several times.   
iii) Combine all the ingredients for the yogurt sauce. Set yogurt sauce aside for at least 
15 minutes to blend flavors. (Sauce can be prepared up to 1 hour in advance and 
refrigerated.)   
iv) Preheat oven broiler on high temperature, with the rack 3 inches from heat source.  
v) Broil steak for about 10 minutes on each side (to a minimum internal temperature of 
145 F). Let cool for 5 minutes before carving. 
vi) Slice thinly across the grain into 12 slices (1 ounce each).* 
vii) Serve three slices of the steak with 1⁄2 cup yogurt sauce on the side. 
4) Grilled Tuna with Chickpea and Spinach salad 
a) 1 Tbsp olive or canola oil; 1 Tbsp garlic, minced (about 2–3 cloves); 2 Tbsp lemon juice; 
1 Tbsp oregano, minced (or 1 tsp dried); 12 oz tuna steaks, cut into 4 portions (3 oz each) 
b) For salad: ½ can (15½ oz) low-sodium chickpeas (or garbanzo beans), drained and 
rinsed; ½ bag (10 oz) leaf spinach, rinsed and dried; 1 Tbsp lemon juice; 1 medium 
tomato, rinsed and cut into wedges; 1/8 tsp salt; 1/8 tsp ground black pepper 
c) Directions 
i) Preheat grill pan or oven broiler (with the rack 3 inches from heat source) on high 
temperature. 
ii) Combine oil, garlic, lemon juice, and oregano, and brush over tuna steaks. Marinate 
for 5–10 minutes. 
iii) Meanwhile, combine all salad ingredients. (Salad can be made up to 2 hours in 
advance and refrigerated.) 
iv) Grill or broil tuna on high heat for 3–4 minutes on each side until the flesh is opaque 
and separates easily with a fork (to a minimum internal temperature of 145 °F). 
v) Serve one tuna steak over 1 cup of mixed salad. 
5) Mixed Veggies # 1 
a) Asparagus; bell peppers; mushrooms 
b) Roasted or sautéed with olive or vegetable oil 
6) Mixed Veggies # 2 
a) Zucchini/squash; carrots; green beans 
b) Steamed 




a) For Chicken: 4 boneless, skinless chicken breasts (3 oz each); 1 egg white; 1 cup fat-free 
evaporated milk; 1 cup breadcrumbs; ¼ cup rolled oats, crushed (pulse a few times in the 
food processor or crush between fingers to make smaller pieces); 1 cup whole-wheat 
flour; 2 tbsp olive oil or vegetable oil 
b) For Salad: 2 tbsp lemon juice; ½ tbsp. olive oil; 4 cups red leaf lettuce, rinsed and dried; 
1 cup cherry tomatoes, rinsed and halved; ¼ tsp salt; ¼ tsp ground black pepper 
c) Directions 
i) Preheat oven to 350 °F. 
ii) Place chicken in a freezer bag with the air squeezed out, and pound each breast down 
to 1⁄2-inch thickness.  
iii) Combine the egg white and evaporated milk in a bowl and mix well. In a separate 
bowl, combine the breadcrumbs and crushed oats, and mix well.  
iv) Coat the chicken breasts in flour and shake off the excess. Dip the chicken breasts in 
the egg and milk mixture and drain off the excess. Then dip the chicken breasts in the 
breadcrumb mixture to coat and shake off the excess. After all chicken breasts have 
been coated, discard any leftover breading mixture.  
v) Heat oil in a large sauté pan. Stir fry the chicken over medium-high heat on one side 
until golden brown, about 2–3 minutes. Turn carefully, and pan fry the second side 
for an additional 2–3 minutes or until golden brown. Remove from the pan, and place 
on paper towels to soak up excess oil. Place on baking sheet, and finish cooking in a 
350°F oven for about 5–8 minutes (to a minimum internal temperature of 165°F). 
vi) For the salad, combine lemon juice and olive oil, and mix well to make a dressing. 
Toss the lettuce leaves and cherry tomatoes with the dressing, salt, and pepper. 
vii) Serve 1 cup salad with one piece of chicken.  
8) Parmesan Rice and Pasta Pilaf 
a) 2 tbsp olive oil; ½ cup thin spaghetti, finely broken, uncooked; 2 tbsp onion, diced; 1 cup 
long-grain white rice, uncooked; 1¼ cups chicken broth, hot; 1¼ cups water, hot; ¼ tsp 
ground white pepper; 1 bay leaf; 2 tbsp shredded parmesan cheese 
b) Directions 
i) In a large sauté pan, heat the oil. Sauté vermicelli and onion until golden brown (for 
about 2–4 minutes) over medium-high heat. Drain off oil.  
ii) Add rice, chicken broth, water, pepper, and bay leaf. Cover and simmer for 15–20 
minutes. Fluff with fork. Cover and let stand for 5 minutes. Remove bay leaf.  
iii) Sprinkle with shredded parmesan cheese and serve immediately. 
9) Pork Mignons with French Applesauce 
a) 1 pair pork tenderloins (about 2 lbs.); 1⁄4 tsp salt; 1/8 tsp ground black pepper;        2 
medium apples, rinsed and cored, but not peeled (try Golden Delicious or Rome); 2 tbsp 
dark seedless raisins; 2 tbsp walnut, broken into coarse pieces;       ½ tsp cinnamon; 
Cooking spray 
b) Directions 
i) Preheat oven broiler on high temperature, with the rack 3 inches from heat source. 
ii) Cover broiler pan with aluminum foil for easy cleanup. Spray foil lightly with 




iii) Cut 8 slices (pork rounds), each 11⁄2 inches thick, from the center of the pair of pork 
tenderloins. Refrigerate or freeze the ends for another use. Place pork rounds on the 
foil-covered broiler pan. Sprinkle with salt and pepper. Set aside a few minutes while 
broiler heats. 
iv) Meanwhile, heat 1⁄2 cup water to boiling in a medium nonstick pan. Slice cored 
apples from top to bottom in 1⁄4-inch wide pieces. Add apples, raisins, walnuts, and 
cinnamon to boiling water. Reduce heat to medium. Cover. Simmer, stirring 
occasionally, until apples are soft and easily pierced with a fork. Set aside until pork 
is cooked. 
v) Broil pork for 5–10 minutes per side (to a minimum internal temperature of 160 °F). 
vi) To serve, place two pork rounds on each dinner plate. Top with ¼ of the applesauce. 
10) Savory Brown Rice 
a) 1 tbsp olive oil; 1 cup onion, chopped; 1 cup portabella mushrooms, rinsed, halved, thinly 
sliced; ½ cup celery, rinsed and finely diced; 2 cups low-sodium chicken broth; 1 cup 
instant brown rice, uncooked; ¼ cup dried parsley; ¼ tsp salt; Add black pepper to taste 
b) Directions 
i) In a 4-quart saucepan, warm olive oil over medium heat. Add onion, mushrooms, and 
celery. Cook and stir for 5–7 minutes, until all vegetables are soft, but not brown.  
ii) Stir in the chicken broth, brown rice, parsley, salt, and pepper. Cover. Bring to a boil 
over high heat.  
iii) Reduce heat to medium. Cook according to brown rice package directions, about 5–
10 minutes. Drain off any excess liquid. Fluff with a fork. Serve immediately. 
11) Teriyaki-glazed salmon with stir-fried vegetables 
a) For Salmon: 2 tbsp light teriyaki sauce; ¼ cup mirin (or sweet rice wine); 2 tbsp rice 
vinegar; 2 tbsp scallions (green onions), rinsed and minced; 1½ tbsp. ginger, minced (or 1 
tsp ground); 12 oz salmon fillets, cut into 4 portions (3 oz each) 
b) For Vegetables: 1 bag (12 oz) frozen vegetable stir-fry; ½ tbsp peanut oil or vegetable oil; 
½ tbsp. garlic, minced (about 1 clove); 1 tbsp ginger, minced (or 1 tsp ground); 1 tbsp 
scallions (green onions), rinsed and minced; 1 tbsp lite soy sauce 
c) Directions 
i) Thaw frozen vegetables in the microwave (or place entire bag in a bowl of hot 
water for about 10 minutes). Set aside until step 7.  
ii) Preheat oven to 350 F.  
iii) Combine teriyaki sauce, mirin, rice vinegar, scallions, and ginger. Mix well. Pour 
over salmon and marinate for 10–15 minutes.  
iv) Remove salmon from the marinade and discard unused portion.  
v) Place salmon on a baking sheet and bake for 10–15 minutes or until fish flakes easily 
with a fork in the thickest part (to a minimum internal temperature of 145 °F).  
vi) Meanwhile, heat oil in a large wok or sauté pan. Add garlic, ginger, and scallions, 
and cook gently but do not brown, about 30 seconds to 1 minute.  
vii) Add vegetables, and continue to stir fry for 2–3 minutes or until heated through. 
Add soy sauce.  
viii) Serve one piece of salmon with 1 cup of vegetables. 
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